1
|
Herrera MC, Johnson J, Lim S, Morales KH, Wilson JD, Hadland SE, Metzger D, Wood S, Dowshen N. Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD). Drug Alcohol Depend 2024; 257:111132. [PMID: 38387256 PMCID: PMC11031309 DOI: 10.1016/j.drugalcdep.2024.111132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 01/22/2024] [Accepted: 02/12/2024] [Indexed: 02/24/2024]
Abstract
BACKGROUND Low rates of HIV pre-exposure prophylaxis (PrEP) prescribing contribute to the disproportionate burden of HIV in the United States. Among adolescent and young adults (AYA) with opioid use disorder, HIV testing and PrEP co-prescription rates are poorly characterized. METHODS We performed a retrospective analysis involving deidentified data from Philadelphia's Medicaid beneficiaries ages 16-29 years who were prescribed medication for opioid use disorder (MOUD) from 2015 to 2020 and continuously Medicaid-enrolled for ≥6 months prior to that prescription. After identifying the presence of a qualifying diagnosis signifying a PrEP indication, we examined the outcome of appropriate PrEP co-prescriptions and HIV testing using generalized estimating equations (GEE) modeling. RESULTS We identified 795 AYA Medicaid beneficiaries with 1269 qualified treatment episodes. We calculated a PrEP prescribing rate of 29.47 per 1000 person-years among AYA receiving MOUD. The HIV testing rate was 63.47 per 1000 person-years among AYA receiving MOUD. GEE modeling revealed that individuals receiving methadone were more likely (aOR=2.62, 95% CI=1.06-6.49) to receive HIV testing within 6 months after a PrEP-qualifying diagnosis compared to those receiving other MOUD medications. Those who only saw outpatient behavioral health providers were less likely (aOR=0.48, 95% CI=0.24-0.99) to have received an HIV test within 6 months after the PrEP-qualifying diagnosis compared to those receiving inpatient behavioral health services. CONCLUSIONS Co-prescription of PrEP and HIV testing among AYA receiving MOUD was rare in this large urban publicly insured population. Interventions are needed to increase HIV prevention services for this key population of AYA at risk for HIV infection.
Collapse
Affiliation(s)
- M C Herrera
- Division of Adolescent Medicine, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
| | - J Johnson
- Department of Behavioral Health and Intellectual disAbility Services, Philadelphia, PA, USA
| | - S Lim
- Department of Behavioral Health and Intellectual disAbility Services, Philadelphia, PA, USA
| | - K H Morales
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - J Deanna Wilson
- Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - S E Hadland
- Division of Adolescent and Young Adult Medicine, MassGeneral for Children / Harvard Medical School, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA
| | - D Metzger
- Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - S Wood
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| | - N Dowshen
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Wood S, Branch J, Vasquez P, DeGuzman MM, Brown A, Sagcal-Gironella AC, Singla S, Ramirez A, Vogel TP. Th17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment. Pediatr Rheumatol Online J 2024; 22:32. [PMID: 38431635 PMCID: PMC10908086 DOI: 10.1186/s12969-024-00965-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 02/11/2024] [Indexed: 03/05/2024] Open
Abstract
BACKGROUND A better understanding of the pathogenesis of polyarticular juvenile idiopathic arthritis (polyJIA) is needed to aide in the development of data-driven approaches to guide selection between therapeutic options. One inflammatory pathway of interest is JAK-STAT signaling. STAT3 is a transcription factor critical to the differentiation of inflammatory T helper 17 cells (Th17s). Previous studies have demonstrated increased STAT3 activation in adult patients with rheumatoid arthritis, but less is known about STAT3 activation in polyJIA. We hypothesized that Th17 cells and STAT3 activation would be increased in treatment-naïve polyJIA patients compared to pediatric controls. METHODS Blood from 17 patients with polyJIA was collected at initial diagnosis and again if remission was achieved (post-treatment). Pediatric healthy controls were also collected. Peripheral blood mononuclear cells were isolated and CD4 + T cell subsets and STAT activation (phosphorylation) were evaluated using flow cytometry. Data were analyzed using Mann-Whitney U and Wilcoxon matched-pairs signed rank tests. RESULTS Treatment-naïve polyJIA patients had increased Th17 cells (CD3 + CD4 + interleukin(IL)-17 +) compared to controls (0.15% v 0.44%, p < 0.05), but Tregs (CD3 + CD4 + CD25 + FOXP3 +) from patients did not differ from controls. Changes in STAT3 phosphorylation in CD4 + T cells following ex vivo stimulation were not significantly different in patients compared to controls. We identified dual IL-17 + and interferon (IFN)γ + expressing CD4 + T cells in patients, but not controls. Further, both Th17/1 s (CCR6 + CD161 + IFNγ + IL-17 +) and ex-Th17s (CCR6 + CD161 + IFNγ + IL-17neg) were increased in patients' post-treatment (Th17/1: 0.3% v 0.07%, p < 0.05 and ex-Th17s: 2.3% v 1.4%, p < 0.05). The patients with the highest IL-17 expressing cells post-treatment remained therapy-bound. CONCLUSIONS Patients with polyJIA have increased baseline Th17 cells, potentially reflecting higher tonic STAT3 activation in vivo. These quantifiable immune markers may identify patients that would benefit upfront from pathway-focused biologic therapies. Our data also suggest that inflammatory CD4 + T cell subsets not detected in controls but increased in post-treatment samples should be further evaluated as a tool to stratify patients in remission on medication. Future work will explore these proposed diagnostic and prognostic biomarkers.
Collapse
Affiliation(s)
- Stephanie Wood
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
- Center for Human Immunobiology, Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Justin Branch
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
- Center for Human Immunobiology, Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Priscilla Vasquez
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Marietta M DeGuzman
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Amanda Brown
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Anna Carmela Sagcal-Gironella
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Saimun Singla
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Andrea Ramirez
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA
| | - Tiphanie P Vogel
- Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA.
- Center for Human Immunobiology, Texas Children's Hospital, 1102 Bates Street Suite 330, Houston, TX, 77030, USA.
| |
Collapse
|
3
|
Bland D, Evans R, Binesmael A, Wood S, Qureshi SP, Fearnley K, Small A, Strain WD, Agius R. Post-acute COVID-19 complications in UK doctors: results of a cross-sectional survey. Occup Med (Lond) 2024; 74:99-103. [PMID: 38078498 DOI: 10.1093/occmed/kqad120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2024] Open
Abstract
BACKGROUND As a consequence of their occupation, doctors and other healthcare workers were at higher risk of contracting coronavirus disease 2019 (COVID-19), and more likely to experience severe disease compared to the general population. However, systematic information on post-acute COVID complications in doctors is very limited. AIMS This study aimed to determine the symptoms, perceived determinants, health and occupational impact, and consequent needs relating to post-acute COVID complications in UK doctors. METHODS An online cross-sectional survey was distributed to UK doctors self-identifying as having Long COVID or other post-acute COVID complications. RESULTS Of 795 responses, 603 fulfilled the inclusion criteria of being a UK-based medical doctor experiencing one or more post-acute COVID complications. Twenty-eight per cent reported a lack of adequate Respiratory Protective Equipment at the time of contracting COVID-19. Eighteen per cent of eligible respondents reported that they had been unable to return to work since acquiring COVID. CONCLUSIONS Post-acute COVID (Long COVID) in UK doctors is a substantial burden for respondents to our questionnaire. The results indicated that insufficient respiratory protection could have contributed to occupational disease, with COVID-19 being contracted in the workplace, and resultant post-COVID complications. Although it may be too late to address the perceived determinants of inadequate protection for those already suffering with Long COVID, more investment is needed in rehabilitation and support of those afflicted.
Collapse
Affiliation(s)
- D Bland
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - R Evans
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - A Binesmael
- Public Health and Healthcare Department, British Medical Association, London, UK
| | - S Wood
- Public Health and Healthcare Department, British Medical Association, London, UK
| | | | - K Fearnley
- Long COVID Doctors for Action, London, UK
| | - A Small
- Chest Heart and Stroke Scotland, Edinburgh, UK
| | - W D Strain
- British Medical Association Board of Science, University of Exeter Medical School, Institute of Clinical and Biomedical Science, Exeter, UK
| | - R Agius
- Council of the British Medical Association, The University of Manchester, Manchester, UK
| |
Collapse
|
4
|
Edmondson J, Hunter J, Bakis G, O’Connor A, Wood S, Qureshi AP. Understanding Post-Esophagectomy Complications and Their Management: The Early Complications. J Clin Med 2023; 12:7622. [PMID: 38137691 PMCID: PMC10743498 DOI: 10.3390/jcm12247622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/24/2023] [Accepted: 12/05/2023] [Indexed: 12/24/2023] Open
Abstract
Esophagectomy is a technically complex operation performed for both benign and malignant esophageal disease. Medical and surgical advancements have led to improved outcomes in esophagectomy patients over the past several decades; however, surgeons must remain vigilant as complications happen often and can be severe. Post-esophagectomy complications can be grouped into early and late categories. The aim of this review is to discuss the early complications of esophagectomy along with their risk factors, work-up, and management strategies with special attention given to anastomotic leaks.
Collapse
Affiliation(s)
| | | | | | | | | | - Alia P. Qureshi
- Division of General Surgery, Oregon Health & Science University, Machall 3186, Portland, OR 97239, USA; (J.E.)
| |
Collapse
|
5
|
Ferraby DH, Hayhurst D, Strachan R, Knapman H, Wood S, Fallowfield JL. Musculoskeletal injuries in UK Service Personnel and the impact of in-theatre rehabilitation during Cold Weather Warfare training: Exercise CETUS 2020. BMJ Mil Health 2023; 169:517-522. [PMID: 35042762 DOI: 10.1136/bmjmilitary-2021-001972] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Accepted: 12/07/2021] [Indexed: 11/04/2022]
Abstract
INTRODUCTION The Royal Marines provide the lead Service for UK Defence Mountain and Cold Weather Warfare capability. This is the first prospective study addressing musculoskeletal injury rates sustained during Cold Weather Warfare training, with the aim of informing injury mitigation interventions and assist military medical planning with respect to delivering primary care rehabilitation in theatre. METHODS All musculoskeletal injuries were surveyed by the Forward Rehabilitation Team (Nov 2019-Mar 2020) during a Cold Weather Deployment to Norway (Ex CETUS 2019/20). The frequency, nature of injury (new or recurrent), onset (sudden or gradual), cause, location and exercise/treatment outcome were recorded. RESULTS Eleven per cent (n=136 cases) of the deployed population (n=1179) reported a musculoskeletal injury, which were mainly 'new' (62%), and with a 'sudden' onset (64%). Injury rate was 17.8 injuries per 10 000 personnel days. The majority of injuries occurred due to military training (88%), specifically during ski-related (61%) and load carriage (10%) activities.The average Service Person treated by the Forward Rehabilitation Team improved from 'injured with restricted duties' to 'fully fit', and with an improvement in their self-reported Musculoskeletal Health Questionnaire from 33 to 45 over an average of two rehabilitation sessions. One hundred and seventeen Service Personnel were able to continue on Ex CETUS with rehabilitation in theatre, thus negating the requirement for aeromedical evacuation for continuation of rehabilitation in the UK. Nineteen patients were unable to continue their Cold Weather Deployment due to the nature of their musculoskeletal injury and returned to the UK for continued care in firm base rehabilitation centres. CONCLUSION This study identifies the nature, causation and injury location. It demonstrates the effectiveness of in-theatre rehabilitation and the ability to treat patients when deployed. Recommendations are presented to support strategies to mitigate musculoskeletal injury risk during future Cold Weather Warfare deployments to Norway.
Collapse
Affiliation(s)
| | - D Hayhurst
- Rehab Div, DMRC Headley Court, Epsom, UK
| | - R Strachan
- Aviation Medicine Training Wing, Centre of Aviation Medicine, RAF Henlow, Bedfordshire, UK
| | - H Knapman
- PCRF, Medical Reception Station, Medical Centre, Dhekelia, UK
| | - S Wood
- HDIS, Specialist Group Military Intelligence (SGMI), Hermitage, Berkshire, UK
| | - J L Fallowfield
- Environmental Medicine and Science Division, Institute of Naval Medicine, Alverstoke, Hampshire, UK
| |
Collapse
|
6
|
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste B, Davey R, Ruben J, Foroudi F, Higgs BG, Lin C, Raman A, Hardcastle N, Shaw M, Mancuso P, Lawrentschuk N, Wood S, Brook N, Kron T, Martin JM, Pryor DI. TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 2023; 117:S3. [PMID: 37784470 DOI: 10.1016/j.ijrobp.2023.06.208] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic body radiotherapy (SBRT) is an emerging non-invasive alternative for primary renal cell cancer (RCC) in patients unsuitable for surgery. The objective of the FASTRACK II clinical trial was to investigate the efficacy of SBRT for primary RCC. MATERIALS/METHODS This non-randomized, intergroup multi-institutional phase II study was activated in 7 Australian centers and 1 Dutch center, through the Trans Tasman Radiation Oncology Group (TROG) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Eligible patients had biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, ECOG performance ≤2 and were medically inoperable, high risk or declined surgery. For tumors ≤4 cm a single fraction of 26 Gy was prescribed, for tumors > 4 cm, 42 Gy in three fractions was prescribed. The primary outcome of the study was to estimate the efficacy of SBRT for primary RCC, defined as local control based on RECIST criteria. The study was powered assuming that 1-year local control would be 90%, with the null hypothesis of ≤80% considered undesirable and not worthy of proceeding to a future randomized controlled trial. RESULTS Between July 2016 and February 2020, 70 patients were enrolled with a median follow-up of 42 months. Median age was 77 years. Forty-nine patients were male (70%), median BMI was 32 and median Charlson comorbidity score was 7. The median [IQR] RENAL complexity score was 8 [7-10]. Biopsy confirmation was 100%. Twenty-three patients (33%) had T1a disease. The median (interquartile range [IQR]) tumor size was 4.6cm [3.7-5.5]; it was 3.3cm [3.0-3.6] in those receiving single fraction (n = 23), and 5.3cm [4.6-6.0] in those receiving 3-fraction SBRT (n = 47). During real-time pre-treatment quality assurance review, 10 cases (14.3%) required resubmission for protocol deviation, 2119 variables were assessed at final review, and final protocol compliance was 99.3%. Seven (10%) patients experienced grade 3 treatment-related adverse events, with no grade 4 or 5 events observed. Eleven (16%) patients reported no adverse events. Local control was 100% throughout the lifetime of the trial (p<0.001). Cancer-specific survival was also 100% throughout the lifetime of the trial. Freedom from distant failure (95% CIs) at 1 and 3 years was 99% (90-100%). Overall survival (95% CIs) at 1 and 3 years was 99% (90-100%) and 82% (70-89%), respectively. Baseline mean eGFR (95% CI) was 61.1 mLs/min (56.6; 65.6) and reduced by -10.8 mLs/min (-13.0; -8.6) by 1-year, by -14.6 mLs/min (-17.0; -12.2) by 2-years and plateaued thereafter. CONCLUSION In the first multicenter prospective trial of a non-surgical primary RCC cohort, enrolling mostly T1b+ disease, SBRT was an effective treatment strategy with no observed local failures. We observed an acceptable side effect profile and renal function after SBRT. These outcomes support the design of a future randomized clinical trial of SBRT versus surgery for primary RCC. The trial was registered with ID: NCT02613819.
Collapse
Affiliation(s)
- S Siva
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - M Bressel
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - M Sidhom
- Liverpool Hospital Cancer Therapy Centre, University of New South Wales, School of Medicine, Sydney, NSW, Australia
| | - S Sridharan
- Calvary Mater Newcastle, Waratah & School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia
| | - B Vanneste
- Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
| | - R Davey
- TROG Cancer Research, Waratah, NSW, Australia
| | - J Ruben
- The William Buckland Radiotherapy Centre, Alfred Health, Melbourne, VIC, Australia
| | - F Foroudi
- Austin Health, Radiation Oncology, Melbourne, Australia
| | - B G Higgs
- Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - C Lin
- Dept of Radiation Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - A Raman
- Royal Newcastle Centre, John Hunter Hospital & School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - N Hardcastle
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - M Shaw
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - P Mancuso
- Urology Department, Liverpool Hospital, Sydney, NSW, Australia
| | - N Lawrentschuk
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - S Wood
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - N Brook
- Department of Surgery, School of Medicine, University of Adelaide, Adelaide, SA, Australia
| | - T Kron
- Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
| | - J M Martin
- Department of Radiation Oncology, Calvary Mater Newcastle & School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - D I Pryor
- Princess Alexandra Hospital, Brisbane, QLD, Australia
| |
Collapse
|
7
|
Wijesooriya K, Larner JM, Read PW, Showalter TN, Lum L, Conaway M, Nguyen C, Lain D, Thakur A, Romano K, McLaughlin C, Jr EMJ, Luminais C, Wood S, Cousins DF, Chen J, Muller DA, Dutta SW, Nesbit EA, Ward KA, Sanders J, Chavis Y, Asare E. Initial Report of a Randomized Trial Comparing Conventional vs. Novel Treatment Planning Technique to Ameliorate Immunosuppression from Lung SBRT. Int J Radiat Oncol Biol Phys 2023; 117:e73-e74. [PMID: 37786124 DOI: 10.1016/j.ijrobp.2023.06.809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) SBRT is highly effective against early-stage non-small cell lung cancer. Radiation Therapy (RT) is known to modulate the immune system and contribute to the generation of anti-tumor T cells and stimulate T cell infiltration into tumors. However, this anti-tumor activity is offset by radiation-induced immunosuppression (RIIS) which results in lower tumor control and survival. Lymphocytes are highly radiosensitive and RIIS means destroying existing as well as newly created cytotoxic and helper T lymphocytes. We hypothesized that optimizing RT treatment planning by considering circulating blood and lymphatics as a critical Organ at Risk (OAR) may mitigate RIIS. MATERIALS/METHODS We conducted an IRB approved NCI funded clinical trial for 50 early-stage lung cancer patients treated with SBRT alone, from 2020 to 2023, to investigate the ability to reduce RIIS by reducing dose to circulating blood and lymphatics with the aid of a predictive algorithm. All SBRT plans adhered to treatment parameters from RTOG 0813 (central) or RTOG 0915 (peripheral). Patients were randomized to two arms: experimental optimization for RIIS (to reduce dose to blood and lymphatic rich organs) versus standard SBRT planning (without optimization for RIIS). Peripheral blood samples were collected at baseline, end of Tx, 4 weeks and 6 months post Tx. Patients with baseline absolute lymphocyte counts (ALC) less than 0.5x109 cells/L were ineligible for the trial. Data acquired for all blood cell types as well as lymphocyte sub populations CD3+, CD4+, CD8+, CD19+, CD56+. Two sample t-test was used to determine the statistical significance between the cohorts at the time points. RESULTS The standard arm had an ALC reduction of 28% at one week post Tx and a nadir at 4 weeks with a 34% reduction. Absolute percentage reductions in ALC from baseline in the optimized arm compared to the standard arm are: end of treatment point (13%, p = 0.03), 4 weeks (12%, p = 0.08), 6 months (15%, p = 0.1), and all three time points together 13% (p = 0.001). ALC recovery appears to be faster in the optimized arm. Radiation induced suppression of all blood cell types are also reduced in the optimized arm with respect to standard arm (relative percentages): ALC (34%), WBC (47%), RBC (46%), platelets (40%), monocytes (100%), and neutrophils (62%) at 4-week mark. Average percentage reductions on integral doses, and V5 (volume receiving a 5 Gy dose) of optimized compared to standard plans are: aorta: 26%, 41% heart: 8%, 33%, vena cava: 32%, 52%, T spine: 51%, 81%, lymph nodes: 35%, 57%, total lung- ITV: 1.6%, 1%, body: 10%, 14%. CONCLUSION For the first time, we have shown that it is possible to reduce RIIS in a statistically significant manner, compared to standard of care, via optimized RT planning using a predictive model. This has implications in increasing the efficacy of immunotherapy by preserving the existing tumor reactive T cells in the immune system to enhance anti-tumor activity, and in reducing hospitalizations and improving survival.
Collapse
Affiliation(s)
- K Wijesooriya
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J M Larner
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - P W Read
- University of Virginia, Charlottesville, VA
| | - T N Showalter
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA; University of Virginia, Charlottesville, VA
| | - L Lum
- University of Virginia, Charlottesville, VA
| | - M Conaway
- University of Virginia, Charlottesville, VA
| | - C Nguyen
- University of Virginia, Charlottesville, VA
| | - D Lain
- University of Virginia, Charlottesville, VA, United States
| | - A Thakur
- University of Virginia, Charlottesville, VA
| | - K Romano
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - C McLaughlin
- University of Virginia, Department of Radiation Oncology, Charlottesville, VA
| | - E M Janowski Jr
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - C Luminais
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - S Wood
- University of Virginia, Charlottesville, VA
| | - D F Cousins
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J Chen
- University of Virginia, Charlottesville, VA
| | - D A Muller
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - S W Dutta
- Department of Radiation Oncology, Emory University, Atlanta, GA
| | - E A Nesbit
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - K A Ward
- Department of Radiation Oncology, University of Virginia, Charlottesville, VA
| | - J Sanders
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| | - Y Chavis
- University of Virginia Health Systems, Charlottesville, VA, United States
| | - E Asare
- University of Virginia Department of Radiation Oncology, Charlottesville, VA
| |
Collapse
|
8
|
Ranjan A, Thoenen EA, Kaida A, Wood S, Van Dyke T, Iwakuma T. Characterization of an Mtbp Hypomorphic Allele in a Diethylnitrosamine-Induced Liver Carcinogenesis Model. Cancers (Basel) 2023; 15:4596. [PMID: 37760565 PMCID: PMC10526184 DOI: 10.3390/cancers15184596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2023] [Revised: 09/11/2023] [Accepted: 09/13/2023] [Indexed: 09/29/2023] Open
Abstract
MTBP is implicated in cell cycle progression, DNA replication, and cancer metastasis. However, the function of MTBP remains enigmatic and is dependent on cellular contexts and its cellular localization. To understand the in vivo physiological role of MTBP, it is important to generate Mtbp knockout mice. However, complete deletion of the Mtbp gene in mice results in early embryonic lethality, while its heterozygous deletion shows modest biological phenotypes, including enhanced cancer metastasis. To overcome this and better characterize the in vivo physiological function of MTBP, we, for the first time, generated mice that carry an Mtbp hypomorphic allele (MtbpH) in which Mtbp protein is expressed at approximately 30% of that in the wild-type allele. We treated wild-type, Mtbp+/-, and MtbpH/- mice with a liver carcinogen, diethylnitrosamine (DEN), and found that the MtbpH/- mice showed worse overall survival when compared to the wild-type mice. Consistent with previous reports using human liver cancer cells, mouse embryonic fibroblasts (MEFs) from the MtbpH/- mice showed an increase in the nuclear localization of p-Erk1/2 and migratory potential. Thus, MtbpH/- mice and cells from MtbpH/- mice are valuable to understand the in vivo physiological role of Mtbp and validate the diverse functions of MTBP that have been observed in human cells.
Collapse
Affiliation(s)
- Atul Ranjan
- Department of Pediatrics, Children’s Mercy Research Institute, Kansas City, MO 64108, USA
| | - Elizabeth A. Thoenen
- Department of Pediatrics, Children’s Mercy Research Institute, Kansas City, MO 64108, USA
| | - Atsushi Kaida
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
| | - Stephanie Wood
- Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
| | | | - Tomoo Iwakuma
- Department of Pediatrics, Children’s Mercy Research Institute, Kansas City, MO 64108, USA
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA
| |
Collapse
|
9
|
Diebolt JH, Yu KM, Wood S, Ziegler A, France A, Villwock MR, Alvi SA, Kakarala K, Shnayder Y, Gan GN, Lominska CE, Neupane P, Bur AM. Prognostic Implications of Skin Invasion in Locally Advanced Oral Cavity Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 2023; 169:69-75. [PMID: 35917167 PMCID: PMC10601021 DOI: 10.1177/01945998221116746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 07/08/2022] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To evaluate the effect of histopathologic skin invasion on 2- and 5-year disease-free survival (DFS) and overall survival (OS) in patients treated with primary surgery for locally advanced oral cavity squamous cell carcinoma (OCSCC). STUDY DESIGN A retrospective case-control study was performed comparing previously untreated patients with pT4a OCSCC with and without skin invasion. SETTING Academic medical center. METHODS Propensity score-matched cohorts were derived by age, sex, surgical margins, pathologic N classification, adjuvant treatment, and primary tumor site. The Kaplan-Meier method was used to evaluate 2- and 5-year OS and DFS, which were compared between cohorts via the log rank (Mantel-Cox) test statistic. RESULTS Overall 25 patients were identified to have pathologic skin invasion, and 50 were selected for the matched control group. OS was significantly lower for patients with skin invasion as compared with controls at 2 years (30.8% vs 53.3%, P = .018) and 5 years (16.6% vs 42.2%, P = .01). DFS was significantly lower for patients with skin invasion vs controls at 2 years (23.7% vs 47.7, P = .037) and 5 years (15.8% vs 41.4%, P = .024). CONCLUSION Histopathologic skin invasion in OCSCC is associated with dismal prognosis in patients who underwent primary surgical treatment. OS outcomes for patients with skin invasion are comparable to survival of patients with recurrent/metastatic disease and T4N2 disease.
Collapse
Affiliation(s)
- Jennifer H. Diebolt
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Katherine M. Yu
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Stephanie Wood
- Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Andrea Ziegler
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Angela France
- Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Mark R. Villwock
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Sameer A. Alvi
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Kiran Kakarala
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Yelizaveta Shnayder
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Gregory N. Gan
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Christopher E. Lominska
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Prakash Neupane
- Department of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Andrés M. Bur
- Department of Otolaryngology–Head and Neck Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA
| |
Collapse
|
10
|
Wood S, Ishida K, Hagerty JR, Karahodza A, Dennis JN, Jolly ER. Characterization of Schistosome Sox Genes and Identification of a Flatworm Class of Sox Regulators. Pathogens 2023; 12:pathogens12050690. [PMID: 37242360 DOI: 10.3390/pathogens12050690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 05/04/2023] [Accepted: 05/05/2023] [Indexed: 05/28/2023] Open
Abstract
Schistosome helminths infect over 200 million people across 78 countries and are responsible for nearly 300,000 deaths annually. However, our understanding of basic genetic pathways crucial for schistosome development is limited. The sex determining region Y-box 2 (Sox2) protein is a Sox B type transcriptional activator that is expressed prior to blastulation in mammals and is necessary for embryogenesis. Sox expression is associated with pluripotency and stem cells, neuronal differentiation, gut development, and cancer. Schistosomes express a Sox-like gene expressed in the schistosomula after infecting a mammalian host when schistosomes have about 900 cells. Here, we characterized and named this Sox-like gene SmSOXS1. SmSoxS1 protein is a developmentally regulated activator that localizes to the anterior and posterior ends of the schistosomula and binds to Sox-specific DNA elements. In addition to SmSoxS1, we have also identified an additional six Sox genes in schistosomes, two Sox B, one SoxC, and three Sox genes that may establish a flatworm-specific class of Sox genes with planarians. These data identify novel Sox genes in schistosomes to expand the potential functional roles for Sox2 and may provide interesting insights into early multicellular development of flatworms.
Collapse
Affiliation(s)
- Stephanie Wood
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Kenji Ishida
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - James R Hagerty
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Anida Karahodza
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Janay N Dennis
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
| | - Emmitt R Jolly
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA
- Center for Global Health and Disease, Case Western Reserve University, Cleveland, OH 44106, USA
| |
Collapse
|
11
|
Abdelfattah N, Kumar P, Wang C, Leu JS, Baskin D, Flynn W, Gao R, Pichumani K, Ijare O, Wood S, Powell S, Haviland D, Kerrigan BP, Lang F, Prabhu S, Huntoon K, Jiang W, Kim B, George J, Yun K. Abstract 5871: Pan-cancer myeloid cell analysis at the single cell level reveals the influence of distinct organ sites in myeloid cell phenotypes and support targeting S100A4 to reverse immune suppression. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
With abundant pro-tumorigenic myeloid cells and few tumoricidal tumor-infiltrating lymphocytes (<5%), GBM is representative of “immune cold” tumors. As such, many different types of immunotherapies have failed to show significant benefits for most glioma patients. Hence, a better understanding of drivers of the immune suppressive microenvironment in GBM and other immune cold tumors is urgently needed to guide future immunotherapy development and application. We recently analyzed 201,986 human glioma and immune cells from 44 tissue fragments from 18 human glioma patients, and present a comprehensive and high-resolution cellular, molecular, and spatial heterogeneity atlas of human glioma. We report an extensive spatial and molecular heterogeneity of glioma and immune cells within the same patient. In addition, we discovered that cell:cell communication between glioma:myeloid cells is considerably more robust than glioma:T-cells, indicating that myeloid cells form a communication hub in vivo. To gain a deeper understanding of these important immune cells, we analyzed 83,479 glioma-infiltrating myeloid cells and identified 9 molecularly distinct myeloid subtypes: 3 microglia subtypes, 3 bone marrow-derived macrophage (BMDM) subtypes, MDSCs, neutrophils, and dendritic cells. Notably, we found that five of these myeloid cell subtype gene signatures are significant predictors of glioma patient survival, independent of glioma cell mutational profiles or gene expression patterns. Leveraging our dataset, we also identified a novel immunotherapy target that is highly expressed in immune-suppressive macrophages and T cells but not in anti-tumor leukocytes: S100A4. We provide both in vitro and in vivo evidence that S100a4 deletion in stromal cells is sufficient to reprogram the immune microenvironment and significantly extend the survival of two independent glioma models. To broaden the potential impact of targeting S100A4 as a selective modulator of immune suppressive leukocytes, we compared the molecular signatures of glioma-associated myeloid cells to those from 12 other cancer types and peripheral blood myeloid cells. We found that S100A4 expression pattern is highly consistent among all tumor types, where its expression is highest in the monocytes and MDSCs and low in most DCs and tissue-resident macrophages. Our preliminary analysis also shows that myeloid cells in gliomas are molecularly distinct from corresponding cell types in other cancers, strongly indicating the role brain microenvironment in influencing the infiltrating BMDM maturation and polarization.
Citation Format: Nourhan Abdelfattah, Parveen Kumar, Caiyi Wang, Jia-Shiun Leu, David Baskin, William Flynn, Ruli Gao, Kumar Pichumani, Omkar Ijare, Stephanie Wood, Suzanne Powell, David Haviland, Brittany Parker Kerrigan, Frederick Lang, Sujit Prabhu, Kristin Huntoon, Wen Jiang, Betty Kim, Joshy George, Kyuson Yun. Pan-cancer myeloid cell analysis at the single cell level reveals the influence of distinct organ sites in myeloid cell phenotypes and support targeting S100A4 to reverse immune suppression. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5871.
Collapse
Affiliation(s)
| | | | - Caiyi Wang
- 1Houston Methodist Research Institute, Houston, TX
| | | | - David Baskin
- 1Houston Methodist Research Institute, Houston, TX
| | | | - Ruli Gao
- 1Houston Methodist Research Institute, Houston, TX
| | | | - Omkar Ijare
- 1Houston Methodist Research Institute, Houston, TX
| | | | | | | | | | | | | | | | | | | | | | - Kyuson Yun
- 1Houston Methodist Research Institute, Houston, TX
| |
Collapse
|
12
|
Zhang Y, Xiang X, Zhou S, Dindar DA, Wood S, Zhang Z, Shan B, Zhao L. Relationship between pathogenic microorganisms and the occurrence of esophageal carcinoma based on pathological type: a narrative review. Expert Rev Gastroenterol Hepatol 2023; 17:353-361. [PMID: 36896656 DOI: 10.1080/17474124.2023.2189099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
Abstract
INTRODUCTION Esophageal cancer (EC) is one of the most common malignant tumors of the upper gastrointestinal tract. The etiology of EC is complicated and increasing evidence has shown that microbial infection is closely related to the occurrence of various malignant tumors. Though many studies have been focused on this subject in recent years, the exact relationship between microbial infection and the occurrence of EC remains unclear. AREAS COVERED In this review, we searched all eligible literature reports, summarized the most recent studies in this research field, and analyzed the pathogenic microorganisms associated with EC, providing the latest evidence and references for the prevention of pathogenic microorganism-related EC. EXPERT OPINION In recent years, increasing evidence has shown that pathogenic microbial infections are closely associated with the development of EC. Therefore, it is necessary to describe in detail the relationship between microbial infection and EC and clarify its possible pathogenic mechanism, which will shed a light on clinical prevention and treatment of cancer caused by pathogenic microbial infection.
Collapse
Affiliation(s)
- Ying Zhang
- Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Xiaohan Xiang
- Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Shaolan Zhou
- Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
| | - Duygu Altinok Dindar
- Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, USA
| | - Stephanie Wood
- Division of Gastrointestinal and General Surgery, School of Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Zhenzhen Zhang
- Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
| | - Baoen Shan
- Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
| | - Lianmei Zhao
- Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.,Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
| |
Collapse
|
13
|
Duran B, Meziani ZE, Joosten S, Jones MK, Prasad S, Peng C, Armstrong W, Atac H, Chudakov E, Bhatt H, Bhetuwal D, Boer M, Camsonne A, Chen JP, Dalton MM, Deokar N, Diefenthaler M, Dunne J, El Fassi L, Fuchey E, Gao H, Gaskell D, Hansen O, Hauenstein F, Higinbotham D, Jia S, Karki A, Keppel C, King P, Ko HS, Li X, Li R, Mack D, Malace S, McCaughan M, McClellan RE, Michaels R, Meekins D, Paolone M, Pentchev L, Pooser E, Puckett A, Radloff R, Rehfuss M, Reimer PE, Riordan S, Sawatzky B, Smith A, Sparveris N, Szumila-Vance H, Wood S, Xie J, Ye Z, Yero C, Zhao Z. Determining the gluonic gravitational form factors of the proton. Nature 2023; 615:813-816. [PMID: 36991189 DOI: 10.1038/s41586-023-05730-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 01/13/2023] [Indexed: 03/31/2023]
Abstract
The proton is one of the main building blocks of all visible matter in the Universe1. Among its intrinsic properties are its electric charge, mass and spin2. These properties emerge from the complex dynamics of its fundamental constituents-quarks and gluons-described by the theory of quantum chromodynamics3-5. The electric charge and spin of protons, which are shared among the quarks, have been investigated previously using electron scattering2. An example is the highly precise measurement of the electric charge radius of the proton6. By contrast, little is known about the inner mass density of the proton, which is dominated by the energy carried by gluons. Gluons are hard to access using electron scattering because they do not carry an electromagnetic charge. Here we investigated the gravitational density of gluons using a small colour dipole, through the threshold photoproduction of the J/ψ particle. We determined the gluonic gravitational form factors of the proton7,8 from our measurement. We used a variety of models9-11 and determined, in all cases, a mass radius that is notably smaller than the electric charge radius. In some, but not all cases, depending on the model, the determined radius agrees well with first-principle predictions from lattice quantum chromodynamics12. This work paves the way for a deeper understanding of the salient role of gluons in providing gravitational mass to visible matter.
Collapse
Affiliation(s)
- B Duran
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - Z-E Meziani
- Physics Division, Argonne National Laboratory, Lemont, IL, USA.
- Department of Physics, Temple University, Philadelphia, PA, USA.
| | - S Joosten
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - M K Jones
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Prasad
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - C Peng
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - W Armstrong
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - H Atac
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - E Chudakov
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - H Bhatt
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - D Bhetuwal
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - M Boer
- Department of Physics, Virginia Polytechnic Institute & State University, Blacksburg, VA, USA
| | - A Camsonne
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J-P Chen
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M M Dalton
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - N Deokar
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - M Diefenthaler
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J Dunne
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - L El Fassi
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - E Fuchey
- Department of Physics, University of Connecticut, Storrs, CT, USA
| | - H Gao
- Department of Physics, Duke University, Durham, NC, USA
| | - D Gaskell
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - O Hansen
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - F Hauenstein
- Department of Physics, Old Dominion University, Norfolk, VA, USA
| | - D Higinbotham
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Jia
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - A Karki
- Department of Physics & Astronomy, Mississippi State University, Mississippi State, MS, USA
| | - C Keppel
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - P King
- Department of Physics and Astronomy, Ohio University, Athens, OH, USA
| | - H S Ko
- CNRS/IN2P3, IJCLab Orsay, Université Paris-Saclay, Gif-sur-Yvette, France
| | - X Li
- Department of Physics, Duke University, Durham, NC, USA
| | - R Li
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - D Mack
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Malace
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - M McCaughan
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - R E McClellan
- Natural Sciences Department, Pensacola State College, Pensacola, FL, USA
| | - R Michaels
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - D Meekins
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - Michael Paolone
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - L Pentchev
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - E Pooser
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Puckett
- Department of Physics, University of Connecticut, Storrs, CT, USA
| | - R Radloff
- Department of Physics and Astronomy, Ohio University, Athens, OH, USA
| | - M Rehfuss
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - B Sawatzky
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - A Smith
- Department of Physics, Duke University, Durham, NC, USA
| | - N Sparveris
- Department of Physics, Temple University, Philadelphia, PA, USA
| | - H Szumila-Vance
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - S Wood
- Experimental Nuclear Physics Division, Thomas Jefferson National Accelerator Facility, Newport News, VA, USA
| | - J Xie
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - Z Ye
- Physics Division, Argonne National Laboratory, Lemont, IL, USA
| | - C Yero
- Department of Physics, Old Dominion University, Norfolk, VA, USA
| | - Z Zhao
- Department of Physics, Duke University, Durham, NC, USA
| |
Collapse
|
14
|
Waddell KJ, Patel MS, Wilkinson JR, Burke RE, Bravata DM, Koganti S, Wood S, Morley JF. Deploying Digital Health Technologies for Remote Physical Activity Monitoring of Rural Populations with Chronic Neurologic Disease. Arch Rehabil Res Clin Transl 2022; 5:100250. [PMID: 36968173 PMCID: PMC10036227 DOI: 10.1016/j.arrct.2022.100250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Objective The objective of this pilot study was to examine the feasibility of a remote physical activity monitoring program, quantify baseline activity levels, and examine predictors of activity among rurally residing adults with Parkinson disease (PD) or stroke. Design Thirty-day observational study. Participants completed standardized assessments, connected a wearable device, and synced daily step counts via a remote monitoring platform. Setting Community-based remote monitoring. Participants Rurally residing adults with PD or stroke enrolled in the Veterans Health Administration. Intervention N/A. Main Outcome Measures Feasibility was evaluated using recruitment data (response rates), study completion (completed assessments and connected the wearable device), and device adherence (days recording ≥100 steps). Daily step counts were examined descriptively. Predictors of daily steps were explored across the full sample, then by diagnosis, using linear mixed-effects regression analyses. Results Forty participants (n=20 PD; n=20 stroke) were included in the analysis with a mean (SD) age of 72.9 (7.6) years. Participants resided 252.6 (105.6) miles from the coordinating site. Recruitment response rates were 11% (PD) and 6% (stroke). Study completion rates were 71% (PD) and 80% (stroke). Device adherence rates were 97.0% (PD) and 95.2% (stroke). Participants with PD achieved a median [interquartile range] of 2618 [3896] steps per day and participants with stroke achieved 4832 [7383] steps. Age was the only significant predictor of daily steps for the full sample (-265 steps, 95% confidence interval [-407, -123]) and by diagnosis (PD, -175 steps, [-335, -15]; stroke, -357 steps [-603, -112]). Conclusions A remote physical activity monitoring program for rurally residing individuals with PD or stroke was feasible. This study establishes a model for a scalable physical activity program for rural, older populations with neurologic conditions from a central coordinating site.
Collapse
|
15
|
Nolan GS, Dunne JA, Lee AE, Wade RG, Kiely AL, Pritchard Jones RO, Gardiner MD, Abbassi O, Abdelaty M, Ahmed F, Ahmed R, Ali S, Allan A, Allen L, Anderson I, Bakir A, Berwick D, Sarala BBN, Bhat W, Bloom O, Bolton L, Brady N, Campbell E, Capitelli-McMahon H, Cassell O, Chalhoub X, Chalmers R, Chan J, Chu HO, Collin T, Cooper K, Curran TA, Cussons D, Daruwalla M, Dearden A, Delikonstantinou I, Dobbs T, Dunlop R, El-Muttardi N, Eleftheriadou A, Elamin SE, Eriksson S, Exton R, Fourie LR, Freethy A, Gardner E, Geh JL, Georgiou A, Georgiou M, Gilbert P, Gkorila A, Green D, Haeney J, Hamilton S, Harper F, Harrison C, Heinze Z, Hemington-Gorse S, Hever P, Hili S, Holmes W, Hughes W, Ibrahim N, Ismail A, Jallali N, James NK, Jemec B, Jica R, Kaur A, Kazzazi D, Khan M, Khan N, Khashaba H, Khera B, Khoury A, Kiely J, Kumar S, Patel PK, Kumbasar DE, Kundasamy P, Kyle D, Langridge B, Liu C, Lo M, Macdonald C, Anandan SM, Mahdi M, Mandal A, Manning A, Markeson D, Matteucci P, McClymont L, Mikhail M, Miller MC, Munro S, Musajee A, Nasrallah F, Ng L, Nicholas R, Nicola A, Nikkhah D, O'Hara N, Odili J, Oudit D, Patel A, Patel C, Patel N, Patel P, Peach H, Phillips B, Pinder R, Pinto-Lopes R, Plonczak A, Quinnen N, Rafiq S, Rahman K, Ramjeeawon A, Rinkoff S, Sainsbury D, Schumacher K, Segaren N, Shahzad F, Shariff Z, Siddiqui A, Singh P, Sludden E, Smith JRO, Song M, Stodell M, Tanos G, Taylor K, Taylor L, Thomson D, Tiernan E, Totty JP, Vaingankar N, Toh V, Wensley K, Whitehead C, Whittam A, Wiener M, Wilson A, Wong KY, Wood S, Yeoh T, Yii NW, Yim G, Young R, Zberea D, Jain A. National audit of non-melanoma skin cancer excisions performed by plastic surgery in the UK. Br J Surg 2022; 109:1040-1043. [DOI: 10.1093/bjs/znac232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022]
Abstract
A national, multi-centre audit of non-melanoma skin cancer excisions by plastic surgery.
Collapse
Affiliation(s)
- Grant S Nolan
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Jonathan A Dunne
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Alice E Lee
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
| | - Ryckie G Wade
- Leeds Institute for Medical Research, University of Leeds , Leeds , UK
- Department of Plastic and Reconstructive Surgery, Leeds Teaching Hospitals NHS Trust , Leeds , UK
| | - Ailbhe L Kiely
- Department of Plastic and Reconstructive Surgery, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust , Fulwood, Preston , UK
| | - Rowan O Pritchard Jones
- Department of Plastic and Reconstructive Surgery, Whiston Hospital, St Helens and Knowsley Teaching Hospitals NHS Trust , Prescot , UK
| | - Matthew D Gardiner
- Department of Plastic and Reconstructive Surgery, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Wexham , Slough , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Abhilash Jain
- Department of Plastic and Reconstructive Surgery, Charing Cross and St Mary’s Hospitals, Imperial College Healthcare NHS Trust , London , UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford , UK
| | | |
Collapse
|
16
|
Ramarao-Milne P, Kondrashova O, Patch AM, Nones K, Koufariotis LT, Newell F, Addala V, Lakis V, Holmes O, Leonard C, Wood S, Xu Q, Mukhopadhyay P, Naeini MM, Steinfort D, Williamson JP, Bint M, Pahoff C, Nguyen PT, Twaddell S, Arnold D, Grainge C, Basirzadeh F, Fielding D, Dalley AJ, Chittoory H, Simpson PT, Aoude LG, Bonazzi VF, Patel K, Barbour AP, Fennell DA, Robinson BW, Creaney J, Hollway G, Pearson JV, Waddell N. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open 2022; 7:100540. [PMID: 35849877 PMCID: PMC9463385 DOI: 10.1016/j.esmoop.2022.100540] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 06/07/2022] [Accepted: 06/19/2022] [Indexed: 12/14/2022] Open
Abstract
Background Next-generation sequencing is used in cancer research to identify somatic and germline mutations, which can predict sensitivity or resistance to therapies, and may be a useful tool to reveal drug repurposing opportunities between tumour types. Multigene panels are used in clinical practice for detecting targetable mutations. However, the value of clinical whole-exome sequencing (WES) and whole-genome sequencing (WGS) for cancer care is less defined, specifically as the majority of variants found using these technologies are of uncertain significance. Patients and methods We used the Cancer Genome Interpreter and WGS in 726 tumours spanning 10 cancer types to identify drug repurposing opportunities. We compare the ability of WGS to detect actionable variants, tumour mutation burden (TMB) and microsatellite instability (MSI) by using in silico down-sampled data to mimic WES, a comprehensive sequencing panel and a hotspot mutation panel. Results We reveal drug repurposing opportunities as numerous biomarkers are shared across many solid tumour types. Comprehensive panels identify the majority of approved actionable mutations, with WGS detecting more candidate actionable mutations for biomarkers currently in clinical trials. Moreover, estimated values for TMB and MSI vary when calculated from WGS, WES and panel data, and are dependent on whether all mutations or only non-synonymous mutations were used. Our results suggest that TMB and MSI thresholds should not only be tumour-dependent, but also be sequencing platform-dependent. Conclusions There is a large opportunity to repurpose cancer drugs, and these data suggest that comprehensive sequencing is an invaluable source of information to guide clinical decisions by facilitating precision medicine and may provide a wealth of information for future studies. Furthermore, the sequencing and analysis approach used to estimate TMB may have clinical implications if a hard threshold is used to indicate which patients may respond to immunotherapy. Genome analysis revealed that treatment biomarkers are shared across solid tumours, highlighting repurposing opportunities. Comprehensive panels detect most known biomarkers; however, WGS detects more biomarkers for treatments in clinical trials. TMB is well correlated between sequencing methods, but absolute values vary and are dependent on mutation types considered.
Collapse
Affiliation(s)
- P Ramarao-Milne
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia; Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia
| | - O Kondrashova
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - A-M Patch
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - K Nones
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - L T Koufariotis
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - F Newell
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - V Addala
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - V Lakis
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - O Holmes
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - C Leonard
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - S Wood
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Q Xu
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - P Mukhopadhyay
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - M M Naeini
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - D Steinfort
- Department of Thoracic Medicine, Royal Melbourne Hospital, Melbourne, Australia
| | - J P Williamson
- Department of Thoracic Medicine, Liverpool Hospital Sydney, Sydney, Australia
| | - M Bint
- Department of Thoracic Medicine, Sunshine Coast University Hospital, Birtinya, Australia
| | - C Pahoff
- Department of Respiratory Medicine, Gold Coast University Hospital, Southport, Australia
| | - P T Nguyen
- Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia
| | - S Twaddell
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - D Arnold
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - C Grainge
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia
| | - F Basirzadeh
- Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - D Fielding
- Department of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - A J Dalley
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - H Chittoory
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - P T Simpson
- UQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - L G Aoude
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - V F Bonazzi
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - K Patel
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia
| | - A P Barbour
- The University of Queensland Diamantina Institute, Faculty of Medicine, University of Queensland, Brisbane, Australia; Upper Gastro-intestinal Surgical Unit, Department of Surgery, Princess Alexandra Hospital, Brisbane, Australia
| | - D A Fennell
- Cancer Research UK Centre Leicester, University of Leicester & University Hospitals of Leicester NHS Trust, Leicester, UK
| | - B W Robinson
- National Centre for Asbestos Related Disease, Institute of Respiratory Health, University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
| | - J Creaney
- National Centre for Asbestos Related Disease, Institute of Respiratory Health, University of Western Australia, Nedlands, Australia; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
| | - G Hollway
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - J V Pearson
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - N Waddell
- Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
| |
Collapse
|
17
|
Georges F, Rashad MNH, Stefanko A, Dlamini M, Karki B, Ali SF, Lin PJ, Ko HS, Israel N, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde CE, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li WB, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Mazouz M, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deeply Virtual Compton Scattering Cross Section at High Bjorken x_{B}. Phys Rev Lett 2022; 128:252002. [PMID: 35802440 DOI: 10.1103/physrevlett.128.252002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 03/28/2022] [Accepted: 04/18/2022] [Indexed: 06/15/2023]
Abstract
We report high-precision measurements of the deeply virtual Compton scattering (DVCS) cross section at high values of the Bjorken variable x_{B}. DVCS is sensitive to the generalized parton distributions of the nucleon, which provide a three-dimensional description of its internal constituents. Using the exact analytic expression of the DVCS cross section for all possible polarization states of the initial and final electron and nucleon, and final state photon, we present the first experimental extraction of all four helicity-conserving Compton form factors (CFFs) of the nucleon as a function of x_{B}, while systematically including helicity flip amplitudes. In particular, the high accuracy of the present data demonstrates sensitivity to some very poorly known CFFs.
Collapse
Affiliation(s)
- F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia, NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Agricultural and Technical State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 6997801, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Longwood University, Farmville, Virginia 23901, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - C E Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W B Li
- University of Regina, Regina, Saskatchewan, S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Mazouz
- Faculté des Sciences de Monastir, Monastir 5019, Tunisia
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipartimento di Fisica delle Università degli di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, Piazzale Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Tunxi, Daizhen Road 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
18
|
Gopalan A, Gallup TD, Wood S, Maldonado J, Margain C, Esnaola NF, Kim MP, Kopetz ES, Yun K. Abstract 694: E-slice: A novel 3D culture platform for precision medicine. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The need for personalized medicine in oncology is widely accepted but translating this important concept into clinical practice has been challenging. Currently, the dominant platform for precision medicine utilizes genomics/sequencing-based assays to measure the expression and/or mutational profiles and then infer patient responses to therapies based on previous knowledge; however, this approach benefits less than 10-15% of patients with profiled tumors. Recognizing the inherent limitations of these inference-based methods, functional assays (e.g., organoids and PDX models) have been developed; however, these approaches also have significant limitations including high cost and time required to establish the models, low “take rates”, and destruction of the native tumor microenvironment (TME). To overcome these challenges, EMPIRI uses a novel 3D ex vivo tumor slice culture method (E-slices) that enables rapid, personalized drug sensitivity testing in intact patient tumor tissues. Major differentiators of the E-slice platform from other ex vivo methods include the use of chemically defined, serum-free medium, longitudinal viability measurements from the same tissue, tracking of dynamic responses to treatment over 2-3 weeks, and retention of the native TME and tissue architecture, unlike other approaches. In addition, E-slices can be generated from any solid tumor tested thus far (breast, lung, colorectal, pancreas, brain, head 7 neck, and others) from patient tumors directly and PDX and genetically engineered mouse models. In addition, because E-slices retain tumor-infiltrating immune cells in their native microenvironment and spatial topography of all cell types in the endogenous configuration, it sustains immune cell survival and proliferation and measures immunotherapy responses ex vivo. The E-slice method is compatible with biopsies as well as surgical samples. Importantly, it has been shown to accurately predict individual patient treatment responses to chemotherapies and targeted therapies in 4-12 days, paving the way for evidence-based personalized treatment selections in a clinically actionable time frame. In summary, we present a novel ex vivo 3D human tumor tissue drug sensitivity platform that faithfully replicates the patient tumor tissues and provides personalized treatment responses in a clinically actionable time frame.
Citation Format: Archana Gopalan, Thomas D. Gallup, Stephanie Wood, Jose Maldonado, Corina Margain, Nestor F. Esnaola, Min P. Kim, E. Scott Kopetz, Kyuson Yun. E-slice: A novel 3D culture platform for precision medicine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 694.
Collapse
Affiliation(s)
| | | | - Stephanie Wood
- 3Houston Methodist/Weill-Cornell Medical College, Houston, TX
| | - Jose Maldonado
- 3Houston Methodist/Weill-Cornell Medical College, Houston, TX
| | | | | | - Min P. Kim
- 3Houston Methodist/Weill-Cornell Medical College, Houston, TX
| | - E. Scott Kopetz
- 3Houston Methodist/Weill-Cornell Medical College, Houston, TX
| | - Kyuson Yun
- 3Houston Methodist/Weill-Cornell Medical College, Houston, TX
| |
Collapse
|
19
|
Abdelfattah N, Kumar P, Wang C, Leu JS, Flynn WW, Gao R, Baskin DS, Pichumani K, Ijare OB, Wood S, Powell S, Haviland D, Lang FF, Prabhu S, Huntoon K, Kerrigan BCP, Jiang WJ, Kim BY, George J, Yun K. Abstract 2540: A multi-dimensional analysis of human gliomas at the single cell level identifies immune suppressive macrophage molecular signatures and a novel immunotherapy target for GBM. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM) is the most prevalent primary brain malignancy in adults. The current standard of care includes maximal surgical resection followed by radio- and chemotherapy with temozolomide. Yet <5% of GBM patients survive more than five years. This indicates a desperate need for more effective treatments, such as immunotherapy for GBM patients. Unfortunately, most immunotherapy trials, including vaccines, adoptive cellular therapy, CAR-T cells, and checkpoint blockade, showed only modest benefits in GBM patients. A major barrier to immunotherapy efficacy is GBM’s immunosuppressive microenvironment composed of few tumor infiltrating lymphocytes (TILs; <5%) but abundant myeloid cells, making it an immune cold tumor. By contrast, immune hot tumors, characterized by abundant tumoricidal effector T cells necessary to mount a meaningful attack, have consistently responded better to immunotherapy. Hence, a better definition of the heterogeneous cell types in the GBM microenvironment and their function is urgently needed. Fortunately, single cell transcriptomics approaches provide comprehensive and high-resolution cellular and molecular understanding to resolve this heterogeneity. Here we report an integrated, multiregional and -dimensional single cell transcriptomic analysis of 201,986 human glioma and immune cells derived from 44 tissue fragments from 18 human glioma patients. In doing so, we map GBM cellular heterotypia and spatial, molecular, and functional heterogeneity of glioma associated immune cells. We report extensive spatial and molecular heterogeneity of glioma cells, microglia, macrophages, and T cells within the same tumor samples in low grade gliomas, primary GBMs, and recurrent GBMs. Importantly, our analysis of 83,479 glioma infiltrating myeloid cells identifies 9 molecularly distinct myeloid subtypes: 4 microglial, 4 bone marrow derived macrophage and dendritic cells subtypes. Importantly, in multiple independent glioma patient cohorts, 5 of these myeloid cell subtype gene signatures were independent predictors of patient survival. We also provide evidence that cell:cell communication between glioma and immune cells is more robust than glioma:Tcells, indicating that myeloid cells form a communication hub in vivo. Additionally, we identified S100A4 as highly expressed in immunosuppressive macrophages and T cells, and provide in vitro and in vivo evidence that S100a4 plays a critical role in promoting immunosuppressive phenotypes in glioma associated leukocytes. This study not only provides the first comprehensive single cell atlas of GBM to include both glioma and immune cells from same samples but also demonstrates its utility in elucidating cell:cell communication among different cell types in vivo and discovering new therapeutic targets for this poorly immunogenic cancer.
Citation Format: Nourhan Abdelfattah, Parveen Kumar, Caiyi Wang, Jia-Shiun Leu, William W. Flynn, Ruli Gao, David S. Baskin, Kumar Pichumani, Omkar B. Ijare, Stephanie Wood, Suzanne Powell, David Haviland, Frederick F. Lang, Sujit Prabhu, Kristin Huntoon, Brittany C. Parker Kerrigan, Wen Jiang Jiang, Betty Y. Kim, Joshy George, Kyuson Yun. A multi-dimensional analysis of human gliomas at the single cell level identifies immune suppressive macrophage molecular signatures and a novel immunotherapy target for GBM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2540.
Collapse
Affiliation(s)
| | | | - Caiyi Wang
- 1Houston Methodist Research Institute, Houston, TX
| | | | | | - Ruli Gao
- 1Houston Methodist Research Institute, Houston, TX
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Kyuson Yun
- 1Houston Methodist Research Institute, Houston, TX
| |
Collapse
|
20
|
Briot K, Liu J, Williams A, Wood S. OP0048 FIRST INTERIM ANALYSIS OF THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: ADULT POPULATION BASELINE CHARACTERISTICS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundX-Linked Hypophosphataemia (XLH) is a rare, progressive, lifelong, hereditary phosphate wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity.1 Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment and other medical interventions on patient outcomes.2 The multicentre, international, XLH patient registry was established to address this lack of information in XLH to help inform future clinical practice.ObjectivesTo report data from the first interim analysis of the International XLH Registry (NCT03193476), focusing on baseline characteristics of adults (aged ≥18 years [y]).MethodsThe International XLH Registry was initiated August 2017 to collect information on the natural history of XLH and will run for 10 years, aiming to recruit 1,200 people with XLH. Subjects diagnosed with XLH were enrolled from 81 sites in 16 countries (Last Patient In: 30/11/2020; Database Lock: 29/03/2021). Parameters collected at baseline included demographics, medical/treatment history, and clinical presentation.ResultsIn total, 217 adults were eligible for inclusion in this analysis (18–<30y, n=56; 30–<50y, n=96; ≥50y, n=65); and 150 (69.1%) were female. Mean (SD) age was 41.9y (15.5y); median 41.1y. Mean height was 155.8 cm (n=79); mean weight, 70.0 kg (n=96); mean BMI 26.5 kg/m2 (n=48). Most subjects resided in the UK (50.7%, n=110) and in France (18.9%, n=41). Treatment data were available for 118 subjects: conventional therapy (phosphate salts and active vitamin D), 83.9% (99/118); burosumab, 11.0% (13/118); no treatment recorded 5.1% (6/118). Of 163 subjects with available data, a genetic test result was recorded for 68 (41.7%), of whom 62 (91.2%) had a confirmed PHEX mutation. Data on XLH family history were available for 187 subjects; 56/140 (40.0%) reported their biological mother was affected; and 22/141 (15.6%) reported their biological father was affected. The mean time to diagnosis from first symptoms was longer in older vs younger adults: 18–<30y, 25 months (mo) (n=21); 30–<50y, 21mo (n=21); ≥50y, 112mo (n=13).Retrospective XLH clinical data were available at study entry for 110 adult subjects. Among these subjects, joint conditions were reported by 36.4% (40/110), with osteoarthritis of the knees (60%), hips (42.5%), and shoulders (22.5%) the most frequently affected. Skeletal abnormalities were noted for 71.8% (79/110) of subjects; most common conditions were genu varum 53.2% (42/79), genu valgum 26.6% (21/79), and enthesopathy 21.5% (17/79). Historical fracture data (“yes/no”) were available for 111 subjects; 41 were reported to have had a fracture. Femur fracture was reported for 22 subjects, and hip fractures for 5 subjects.Details of historical orthopaedic surgery were reported for 99 adults; osteotomy was reported for 89 subjects, and hip replacements reported in 14 subjects.ConclusionThe demographics and baseline characteristics of subjects in the International XLH Registry are as expected for adults with XLH. The shorter time to diagnosis in younger vs older adults may indicate improved recognition and diagnosis of XLH in recent years. The analysis of this young population treated with conventional therapy highlights the frequency of musculoskeletal involvement (osteoarthritis, enthesopathies, etc). The information collected within this rare-disease registry during these 10 years provides an exciting opportunity to integrate large-scale real-world evidence into clinical practice, with the aim of improving the care and quality of life of people living with this debilitating disease.References[1]Haffner D, et al. Nat Rev Nephrol 2019;15(7):435–455.[2]Padidela R, et al. Orphanet J Rare Dis. 2020; 15:172.AcknowledgementsThe authors acknowledge the contribution of all members of the International XLH Registry Steering Committee.Disclosure of InterestsKarine Briot Speakers bureau: Speakers bureau from KKI, Amgen, UCB, Alexion, Jonathan Liu Employee of: Employed by Kyowa Kirin International, Angela Williams Employee of: Employed by Kyowa Kirin International, Sue Wood Employee of: Employed by Kyowa Kirin International.
Collapse
|
21
|
Ariceta G, Liu J, Williams A, Wood S, Schnabel D. POS1155 THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: OVERVIEW OF THE DATA SET. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundX-Linked Hypophosphataemia (XLH) is a rare, progressive, lifelong, hereditary renal tubule phosphate-wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity.1 Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment on patient outcomes.2 The International XLH Registry was established to address this lack of information on XLH to help inform future clinical management. The Registry will collect data to characterise the treatment, burden of disease, disease progression and long-term outcomes of XLH.ObjectivesTo provide an overview and status update of the International XLH Registry as of 31 December 2021.MethodsThe International XLH Registry (NCT03193476) was initiated in August 2017, aims to recruit 1,200 children and adults with XLH, and will run for 10 years. This Registry is an international, multicentre, non-interventional data collection programme and will provide the largest single dataset representing children and adults with XLH. To be eligible for inclusion in the registry, patients must meet all the following criteria:1) Male or female subjects of all ages; 2) Diagnosis of XLH with clinical, radiological, biochemical and/or genetic findings consistent with XLH. The Registry captures any treatment details and clinical outcome variables in patients with XLH and patients are followed for as long as informed consent (and assent, where applicable) and regulatory permissions are maintained. Only data collected during standard routine examinations are recorded within the Registry, and no specific examinations/data entries are mandated.Parameters collected at baseline included demographics, medical and treatment history, and clinical presentation data. The conduct of the International XLH Registry is overseen by 17 Steering Committee physician members representing the region.ResultsAs of 31 December 2021, 1,043 subjects diagnosed with XLH were enrolled from 88 hospital sites in 19 countries. The geographic distribution of subjects is as follows: Belgium n=29, Bulgaria n=7, Czech Republic n=8, Denmark n=23, France n=267, Germany n=79, Hungary n=11, Ireland n=5, Israel n=21, Italy n=88, The Netherlands n=26, Norway n=23, Portugal n=9, Slovakia n=5, Slovenia n=3, Spain n=55, Sweden n=43, Switzerland n=17, and the UK n=324. A further 30 sites are yet to enrol (including sites in Austria and Latvia). Overall, 400 adults (18–29y, n=116; 30–39y, n=81; 40–49y, n=95; 50–59y, n=58; ≥60y, n=50) and 620 paediatric subjects (<5y, n=138; 5–12y, n=321; 13–17y, n=161) have been enrolled (date of birth not reported, n=23). The majority of enrolled subjects are female (648 (62.1%), with 372 male (35.7%) and 23 for whom sex was not reported (2.2%). The quantity of data from the patients included in this Registry will enable ongoing snapshot and prospective analyses to be conducted over the coming years to answer research questions and inform clinical practice.ConclusionThis International XLH Registry forms the largest dataset of subjects with XLH collected to date. Patients have been recruited from a wide geographical region and baseline demographics are consistent with a hereditary X-linked dominant disease. Information collected during the 10-year Registry duration will generate real-world evidence to help inform clinical practice throughout the region, with the aim of improving the care and quality of life of adults and children living with this debilitating disease.References[1]Haffner D, et al. Nat Rev Nephrol 2019;15(7):435–455.[2]Padidela R, et al. Orphanet J Rare Dis. 2020; 15:172.AcknowledgementsAuthors acknowledge the contribution of all International XLH Registry Steering Committee members, and all the investigators participating in the International XLH Registry.Disclosure of InterestsGema Ariceta Speakers bureau: I have received honoraria for lectures, presentations, or educational events from Alexion Pharmaceuticals, Recordati Rare Disease, Advicenne, Chiesi, Kyowa Kirin, Consultant of: I have participated on Advisory Boards for Alexion Pharmaceuticals, Advicenne, Chiesi, Dicerna, and Alnylam., Jonathan Liu Employee of: Employee of Kyowa Kirin International, Angela Williams Employee of: Employee of Kyowa Kirin International, Sue Wood Employee of: Employee of Kyowa Kirin International, Dirk Schnabel Speakers bureau: I received an honorarium from various companies for scientific lectures (i.e. Ascendis, BioMarin, Ferring Pharma, Hexal / Sandoz, Ipsen Pharma, Kyowa Kirin, Merck Serono, Novo Nordisk), Consultant of: BioMarin, Kyowa Kirin
Collapse
|
22
|
Abrams D, Albataineh H, Aljawrneh BS, Alsalmi S, Androic D, Aniol K, Armstrong W, Arrington J, Atac H, Averett T, Gayoso CA, Bai X, Bane J, Barcus S, Beck A, Bellini V, Bhatt H, Bhetuwal D, Biswas D, Blyth D, Boeglin W, Bulumulla D, Butler J, Camsonne A, Carmignotto M, Castellanos J, Chen JP, Cohen EO, Covrig S, Craycraft K, Cruz-Torres R, Dongwi B, Duran B, Dutta D, Fuchey E, Gal C, Gautam TN, Gilad S, Gnanvo K, Gogami T, Gomez J, Gu C, Habarakada A, Hague T, Hansen JO, Hattawy M, Hauenstein F, Higinbotham DW, Holt RJ, Hughes EW, Hyde C, Ibrahim H, Jian S, Joosten S, Karki A, Karki B, Katramatou AT, Keith C, Keppel C, Khachatryan M, Khachatryan V, Khanal A, Kievsky A, King D, King PM, Korover I, Kulagin SA, Kumar KS, Kutz T, Lashley-Colthirst N, Li S, Li W, Liu H, Liuti S, Liyanage N, Markowitz P, McClellan RE, Meekins D, Beck SMT, Meziani ZE, Michaels R, Mihovilovic M, Nelyubin V, Nguyen D, Nycz M, Obrecht R, Olson M, Owen VF, Pace E, Pandey B, Pandey V, Paolone M, Papadopoulou A, Park S, Paul S, Petratos GG, Petti R, Piasetzky E, Pomatsalyuk R, Premathilake S, Puckett AJR, Punjabi V, Ransome RD, Rashad MNH, Reimer PE, Riordan S, Roche J, Salmè G, Santiesteban N, Sawatzky B, Scopetta S, Schmidt A, Schmookler B, Segal J, Segarra EP, Shahinyan A, Širca S, Sparveris N, Su T, Suleiman R, Szumila-Vance H, Tadepalli AS, Tang L, Tireman W, Tortorici F, Urciuoli GM, Wojtsekhowski B, Wood S, Ye ZH, Ye ZY, Zhang J. Measurement of the Nucleon F_{2}^{n}/F_{2}^{p} Structure Function Ratio by the Jefferson Lab MARATHON Tritium/Helium-3 Deep Inelastic Scattering Experiment. Phys Rev Lett 2022; 128:132003. [PMID: 35426713 DOI: 10.1103/physrevlett.128.132003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 01/23/2022] [Accepted: 02/09/2022] [Indexed: 06/14/2023]
Abstract
The ratio of the nucleon F_{2} structure functions, F_{2}^{n}/F_{2}^{p}, is determined by the MARATHON experiment from measurements of deep inelastic scattering of electrons from ^{3}H and ^{3}He nuclei. The experiment was performed in the Hall A Facility of Jefferson Lab using two high-resolution spectrometers for electron detection, and a cryogenic target system which included a low-activity tritium cell. The data analysis used a novel technique exploiting the mirror symmetry of the two nuclei, which essentially eliminates many theoretical uncertainties in the extraction of the ratio. The results, which cover the Bjorken scaling variable range 0.19<x<0.83, represent a significant improvement compared to previous SLAC and Jefferson Lab measurements for the ratio. They are compared to recent theoretical calculations and empirical determinations of the F_{2}^{n}/F_{2}^{p} ratio.
Collapse
Affiliation(s)
- D Abrams
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 78363, USA
| | - B S Aljawrneh
- North Carolina A & T State University, Greensboro, North Carolina 27411, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
- King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
| | - D Androic
- University of Zagreb, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, California 90032, USA
| | - W Armstrong
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Arrington
- Argonne National Laboratory, Lemont, Illinois 60439, USA
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William & Mary, Williamsburg, Virginia 23187, USA
| | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - H Bhatt
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - D Blyth
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33199, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Butler
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - A Camsonne
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - J-P Chen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - S Covrig
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - K Craycraft
- William & Mary, Williamsburg, Virginia 23187, USA
| | - R Cruz-Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Dongwi
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Dutta
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T N Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Gogami
- Tohoku University, Sendai 980-8576, Japan
| | - J Gomez
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - J-O Hansen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Hattawy
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | | | - R J Holt
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - E W Hughes
- Columbia University, New York, New York 10027, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, Giza 12613 Egypt
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Karki
- Mississippi State University, Mississipi State, Mississippi 39762, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | | | - C Keith
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Keppel
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - A Kievsky
- Istituto Nazionale di Fisica Nucleare, Sezione di Pisa, 56127 Pisa, Italy
| | - D King
- Syracuse University, Syracuse, New York 13244, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - I Korover
- Nuclear Research Center-Negev, Beer-Sheva 84190, Israel
| | - S A Kulagin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - K S Kumar
- Stony Brook, State University of New York, New York 11794, USA
| | - T Kutz
- Stony Brook, State University of New York, New York 11794, USA
| | | | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2, Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - S Liuti
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | | | - D Meekins
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z-E Meziani
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Michaels
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Mihovilovic
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
- Institut für Kernphysik, Johannes Gutenberg-Universität, Mainz 55122, Germany
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Olson
- Saint Norbert College, De Pere, Wisconsin 54115, USA
| | - V F Owen
- William & Mary, Williamsburg, Virginia 23187, USA
| | - E Pace
- University of Rome Tor Vergata and INFN, Sezione di Roma Tor Vergata, 00133 Rome, Italy
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - V Pandey
- Center for Neutrino Physics, Virginia Tech, Blacksburg, Virginia 24061, USA
| | - M Paolone
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Papadopoulou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - S Paul
- William & Mary, Williamsburg, Virginia 23187, USA
| | | | - R Petti
- University of South Carolina, Columbia, South Carolina 29208, USA
| | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel
| | - R Pomatsalyuk
- Institute of Physics and Technology, 61108 Kharkov, Ukraine
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R D Ransome
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - G Salmè
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | - N Santiesteban
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - B Sawatzky
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Scopetta
- University of Perugia and INFN, Sezione di Perugia, 06123 Perugia, Italy
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Segal
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Shahinyan
- Yerevan Physics Institute, Yerevan 375036, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana 1000, Slovenia
- Jožef Stefan Institute, Ljubljana, Slovenia
| | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
- Shandong Institute of Advanced Technology, Jinan, Shandong 250100, China
| | - R Suleiman
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - A S Tadepalli
- Rutgers, The State University of New Jersey, Piscataway, New Jersey 08855, USA
| | - L Tang
- Hampton University, Hampton, Virginia 23669, USA
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - W Tireman
- Northern Michigan University, Marquette, Michigan 49855, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Sezione di Catania, 95123 Catania, Italy
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma, 00185 Rome, Italy
| | | | - S Wood
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - Z H Ye
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Z Y Ye
- University of Illinois-Chicago, Chicago, Illinois 60607, USA
| | - J Zhang
- Stony Brook, State University of New York, New York 11794, USA
| |
Collapse
|
23
|
Willis TA, Wood S, Brehaut J, Colquhoun H, Brown B, Lorencatto F, Foy R. Opportunities to improve the impact of two national clinical audit programmes: a theory-guided analysis. Implement Sci Commun 2022; 3:32. [PMID: 35313992 PMCID: PMC8935621 DOI: 10.1186/s43058-022-00275-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/19/2022] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Audit and feedback is widely used in healthcare improvement, with evidence of modest yet potentially important effects upon professional practice. There are approximately 60 national clinical audit programmes in the UK. These programmes often develop and adapt new ways of delivering feedback to optimise impacts on clinical practice. Two such programmes, the National Diabetes Audit (NDA) and the Trauma Audit Research Network (TARN), recently introduced changes to their delivery of feedback. We assessed the extent to which the design of these audit programmes and their recent changes were consistent with best practice according to the Clinical Performance Feedback Intervention Theory (CP-FIT). This comprehensive framework specifies how variables related to the feedback itself, the recipient, and the context operate via explanatory mechanisms to influence feedback success.
Methods
We interviewed 19 individuals with interests in audit and feedback, including researchers, audit managers, healthcare staff, and patient and public representatives. This range of expert perspectives enabled a detailed exploration of feedback from the audit programmes. We structured interviews around the CP-FIT feedback cycle and its component processes (e.g. Data collection and analysis, Interaction). Our rapid analytic approach explored the extent to which both audits applied features consistent with CP-FIT.
Results
Changes introduced by the audit programmes were consistent with CP-FIT. Specifically, the NDA’s increased frequency of feedback augmented existing strengths, such as automated processes (CP-FIT component: Data collection and analysis) and being a credible source of feedback (Acceptance). TARN’s new analytic tool allowed greater interactivity, enabling recipients to interrogate their data (Verification; Acceptance). We also identified scope for improvement in feedback cycles, such as targeting of feedback recipients (Interaction) and feedback complexity (Perception) for the NDA and specifying recommendations (Intention) and demonstrating impact (Clinical performance improvement) for TARN.
Conclusions
The changes made by the two audit programmes appear consistent with suggested best practice, making clinical improvement more likely. However, observed weaknesses in the feedback cycle may limit the benefits of these changes. Applying CP-FIT via a rapid analysis approach helps identify strengths and remediable weaknesses in the design of audit programmes that can be shared with them in a timely manner.
Collapse
|
24
|
Christy ME, Gautam T, Ou L, Schmookler B, Wang Y, Adikaram D, Ahmed Z, Albataineh H, Ali SF, Aljawrneh B, Allada K, Allison SL, Alsalmi S, Androic D, Aniol K, Annand J, Arrington J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Bhatt H, Bhetuwal D, Biswas D, Brash E, Bulumulla D, Camacho CM, Campbell J, Camsonne A, Carmignotto M, Castellanos J, Chen C, Chen JP, Chetry T, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, Deconinck W, Defurne M, Desnault C, Di D, Dlamini M, Duer M, Duran B, Ent R, Fanelli C, Fuchey E, Gal C, Gaskell D, Georges F, Gilad S, Glamazdin O, Gnanvo K, Gramolin AV, Gray VM, Gu C, Habarakada A, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Hernandez AV, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Israel N, Jen CM, Jin K, Jones M, Kabir A, Karki B, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu H, Liu J, Liyanage AH, Mack D, Magee J, Malace S, Mammei J, Markowitz P, Mayilyan S, McClellan E, Meddi F, Meekins D, Mesick K, Michaels R, Mkrtchyan A, Moffit B, Montgomery R, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obrecht RF, Ohanyan K, Palatchi C, Pandey B, Park K, Park S, Peng C, Persio FD, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Rashad MNH, Reimer PE, Riordan S, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Shabestari MH, Shahinyan A, Širca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Stefanko A, Su T, Subedi A, Sulkosky V, Sun A, Tan Y, Thorne L, Ton N, Tortorici F, Trotta R, Uniyal R, Urciuoli GM, Voutier E, Waidyawansa B, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye ZH, Yero C, Zhang J, Zhao YX, Zhu P. Form Factors and Two-Photon Exchange in High-Energy Elastic Electron-Proton Scattering. Phys Rev Lett 2022; 128:102002. [PMID: 35333083 DOI: 10.1103/physrevlett.128.102002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 11/06/2021] [Accepted: 01/31/2022] [Indexed: 06/14/2023]
Abstract
We present new precision measurements of the elastic electron-proton scattering cross section for momentum transfer (Q^{2}) up to 15.75 (GeV/c)^{2}. Combined with existing data, these provide an improved extraction of the proton magnetic form factor at high Q^{2} and double the range over which a longitudinal or transverse separation of the cross section can be performed. The difference between our results and polarization data agrees with that observed at lower Q^{2} and attributed to hard two-photon exchange (TPE) effects, extending to 8 (GeV/c)^{2} the range of Q^{2} for which a discrepancy is established at >95% confidence. We use the discrepancy to quantify the size of TPE contributions needed to explain the cross section at high Q^{2}.
Collapse
Affiliation(s)
- M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Wang
- William and Mary, Williamsburg, Virginia 23185, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 77843, USA
| | - S F Ali
- Catholic University of America, Washington, District of Columbia 20064, USA
| | - B Aljawrneh
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
- Al Zaytoonah University of Jordan, Amman 11733, Jordan
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S L Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000, Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - J Arrington
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- William and Mary, Williamsburg, Virginia 23185, USA
| | | | - X Bai
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Bhatt
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C M Camacho
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - J Campbell
- Dalhousie University, Nova Scotia NS B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- William and Mary, Williamsburg, Virginia 23185, USA
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina A&T State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - W Deconinck
- William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - M Duer
- Tel Aviv University, Tel Aviv-Yafo 69978, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Georges
- Ecole Centrale Paris, 3 Rue Joliot Curie, 91190 Gif-sur-Yvette, France
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A V Gramolin
- Boston University, Boston, Massachusetts 02215, USA
| | - V M Gray
- William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A V Hernandez
- Catholic University of America, Washington, DC 20064, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashland, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo, 12613, Egypt
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - C-M Jen
- Virginia Polytechnic Institute and State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - J Liu
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - A H Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - D Mack
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Magee
- William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - S Mayilyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesick
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - B Moffit
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R F Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - K Ohanyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - F D Persio
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Stony Brook, State University of New York, New York 11794, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Širca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tan
- Shandong University, Shandong, Jinan 250100, China
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - N Ton
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Department of Physics and Astronomy, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, Pittsburgh, Pennsylvania 15282, USA
| | - R Uniyal
- Catholic University of America, Washington, DC 20064, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare - Sezione di Roma, P.le Aldo Moro, 2 - 00185 Roma, Italy
| | - E Voutier
- Institut de Physique Nucleaire, 15 Rue Georges Clemenceau, 91400 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, 44 Daizhen Road, Tunxi District, Huangshan, Anhui Province, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z H Ye
- University of Virginia, Charlottesville, Virginia 232904, USA
- Tsinghua University, 30 Shuangqing Rd, Haidian District, Beijing 100190, China
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 232904, USA
| | - Y X Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
25
|
Wood S, Newman M, Batting M, Barker K. Is the squat test a valid and reliable test for the diagnosis of femoral acetabular impingement? A systematic review. Physiotherapy 2022. [DOI: 10.1016/j.physio.2021.12.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Lyo V, Stroud A, Wood S, Macht R, Carter J, Rogers S, Husain F. Reoperations after Sleeve Gastrectomy: A Dual Academic Institutional Experience. Surg Obes Relat Dis 2022; 18:641-649. [DOI: 10.1016/j.soard.2022.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 11/22/2021] [Accepted: 01/03/2022] [Indexed: 11/25/2022]
|
27
|
Dlamini M, Karki B, Ali SF, Lin PJ, Georges F, Ko HS, Israel N, Rashad MNH, Stefanko A, Adikaram D, Ahmed Z, Albataineh H, Aljawrneh B, Allada K, Allison S, Alsalmi S, Androic D, Aniol K, Annand J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Bartlett K, Bellini V, Beminiwattha R, Bericic J, Biswas D, Brash E, Bulumulla D, Campbell J, Camsonne A, Carmignotto M, Castellano J, Chen C, Chen JP, Chetry T, Christy ME, Cisbani E, Clary B, Cohen E, Compton N, Cornejo JC, Covrig Dusa S, Crowe B, Danagoulian S, Danley T, De Persio F, Deconinck W, Defurne M, Desnault C, Di D, Duer M, Duran B, Ent R, Fanelli C, Franklin G, Fuchey E, Gal C, Gaskell D, Gautam T, Glamazdin O, Gnanvo K, Gray VM, Gu C, Hague T, Hamad G, Hamilton D, Hamilton K, Hansen O, Hauenstein F, Henry W, Higinbotham DW, Holmstrom T, Horn T, Huang Y, Huber GM, Hyde C, Ibrahim H, Jen CM, Jin K, Jones M, Kabir A, Keppel C, Khachatryan V, King PM, Li S, Li W, Liu J, Liu H, Liyanage A, Magee J, Malace S, Mammei J, Markowitz P, McClellan E, Meddi F, Meekins D, Mesik K, Michaels R, Mkrtchyan A, Montgomery R, Muñoz Camacho C, Myers LS, Nadel-Turonski P, Nazeer SJ, Nelyubin V, Nguyen D, Nuruzzaman N, Nycz M, Obretch OF, Ou L, Palatchi C, Pandey B, Park S, Park K, Peng C, Pomatsalyuk R, Pooser E, Puckett AJR, Punjabi V, Quinn B, Rahman S, Reimer PE, Roche J, Sapkota I, Sarty A, Sawatzky B, Saylor NH, Schmookler B, Shabestari MH, Shahinyan A, Sirca S, Smith GR, Sooriyaarachchilage S, Sparveris N, Spies R, Su T, Subedi A, Sulkosky V, Sun A, Thorne L, Tian Y, Ton N, Tortorici F, Trotta R, Urciuoli GM, Voutier E, Waidyawansa B, Wang Y, Wojtsekhowski B, Wood S, Yan X, Ye L, Ye Z, Yero C, Zhang J, Zhao Y, Zhu P. Deep Exclusive Electroproduction of π^{0} at High Q^{2} in the Quark Valence Regime. Phys Rev Lett 2021; 127:152301. [PMID: 34678020 DOI: 10.1103/physrevlett.127.152301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 06/07/2021] [Accepted: 08/17/2021] [Indexed: 06/13/2023]
Abstract
We report measurements of the exclusive neutral pion electroproduction cross section off protons at large values of x_{B} (0.36, 0.48, and 0.60) and Q^{2} (3.1 to 8.4 GeV^{2}) obtained from Jefferson Lab Hall A experiment E12-06-014. The corresponding structure functions dσ_{T}/dt+εdσ_{L}/dt, dσ_{TT}/dt, dσ_{LT}/dt, and dσ_{LT^{'}}/dt are extracted as a function of the proton momentum transfer t-t_{min}. The results suggest the amplitude for transversely polarized virtual photons continues to dominate the cross section throughout this kinematic range. The data are well described by calculations based on transversity generalized parton distributions coupled to a helicity flip distribution amplitude of the pion, thus providing a unique way to probe the structure of the nucleon.
Collapse
Affiliation(s)
- M Dlamini
- Ohio University, Athens, Ohio 45701, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | - S F Ali
- Catholic University of America, Washington, DC 20064, USA
| | - P-J Lin
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - F Georges
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - H-S Ko
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826 Seoul, Korea
| | - N Israel
- Ohio University, Athens, Ohio 45701, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Stefanko
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - D Adikaram
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Z Ahmed
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - H Albataineh
- Texas A&M University-Kingsville, Kingsville, Texas 78363, USA
| | - B Aljawrneh
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - K Allada
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Allison
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - S Alsalmi
- Kent State University, Kent, Ohio 44240, USA
| | - D Androic
- University of Zagreb, Trg Republike Hrvatske 14, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, Los Angeles, California 90032, USA
| | - J Annand
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - K Bartlett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - V Bellini
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | | | - J Bericic
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - E Brash
- Christopher Newport University, Newport News, Virginia 23606, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - J Campbell
- Dalhousie University, Nova Scotia B3H 4R2, Canada
| | - A Camsonne
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - M Carmignotto
- Catholic University of America, Washington, DC 20064, USA
| | - J Castellano
- Florida International University, Miami, Florida 33199, USA
| | - C Chen
- Hampton University, Hampton, Virginia 23669, USA
| | - J-P Chen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Chetry
- Ohio University, Athens, Ohio 45701, USA
| | - M E Christy
- Hampton University, Hampton, Virginia 23669, USA
| | - E Cisbani
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - B Clary
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - E Cohen
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - N Compton
- Ohio University, Athens, Ohio 45701, USA
| | - J C Cornejo
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Covrig Dusa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - B Crowe
- North Carolina Central University, Durham, North Carolina 27707, USA
| | - S Danagoulian
- North Carolina Ag. and Tech. State University, Greensboro, North Carolina 27411, USA
| | - T Danley
- Ohio University, Athens, Ohio 45701, USA
| | - F De Persio
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - W Deconinck
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - M Defurne
- CEA Saclay, 91191 Gif-sur-Yvette, France
| | - C Desnault
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - D Di
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Duer
- Tel Aviv University, Tel Aviv 699780 1, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Ent
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - C Fanelli
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - G Franklin
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Gaskell
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - O Glamazdin
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - V M Gray
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - G Hamad
- Ohio University, Athens, Ohio 45701, USA
| | - D Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - K Hamilton
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - O Hansen
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - W Henry
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D W Higinbotham
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - T Holmstrom
- Randolph Macon College, Ashlan, Virginia 23005, USA
| | - T Horn
- Catholic University of America, Washington, DC 20064, USA
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Huang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - G M Huber
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, Cairo 121613, Egypt
| | - C-M Jen
- Virginia Polytechnic Institute & State University, Blacksburg, Virginia 234061, USA
| | - K Jin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - M Jones
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Kabir
- Kent State University, Kent, Ohio 44240, USA
| | - C Keppel
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - V Khachatryan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
- Stony Brook, State University of New York, New York 11794, USA
- Cornell University, Ithaca, New York 14853, USA
| | - P M King
- Ohio University, Athens, Ohio 45701, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - W Li
- University of Regina, Regina, Saskatchewan S4S 0A2 Canada
| | - J Liu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - A Liyanage
- Hampton University, Hampton, Virginia 23669, USA
| | - J Magee
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - S Malace
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J Mammei
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | - E McClellan
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - F Meddi
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - D Meekins
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - K Mesik
- Rutgers University, New Brunswick, New Jersey 08854, USA
| | - R Michaels
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A Mkrtchyan
- Catholic University of America, Washington, DC 20064, USA
| | - R Montgomery
- SUPA School of Physics and Astronomy, University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - C Muñoz Camacho
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - L S Myers
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - P Nadel-Turonski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S J Nazeer
- Hampton University, Hampton, Virginia 23669, USA
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - D Nguyen
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - O F Obretch
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - C Palatchi
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - K Park
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - C Peng
- Duke University, Durham, North Carolina 27708, USA
| | - R Pomatsalyuk
- Kharkov Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - E Pooser
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - B Quinn
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - S Rahman
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - I Sapkota
- Catholic University of America, Washington, DC 20064, USA
| | - A Sarty
- Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - B Sawatzky
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - N H Saylor
- Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - M H Shabestari
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A Shahinyan
- AANL, 2 Alikhanian Brothers Street, 0036 Yerevan, Armenia
| | - S Sirca
- Faculty of Mathematics and Physics, University of Ljubljana, 1000 Ljubljana, Slovenia
| | - G R Smith
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | - N Sparveris
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - R Spies
- University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - A Subedi
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - V Sulkosky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Sun
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - L Thorne
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA
| | - Y Tian
- Shandong University, Jinan, Shandong, 250100, China
| | - N Ton
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - F Tortorici
- Istituto Nazionale di Fisica Nucleare, Dipt. Di Fisica delle Uni. di Catania, I-95123 Catania, Italy
| | - R Trotta
- Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA
| | - G M Urciuoli
- Istituto Nazionale di Fisica Nucleare-Sezione di Roma, P.le Aldo Moro, 2-00185 Roma, Italy
| | - E Voutier
- Université Paris-Saclay, CNRS/IN2P3, IJCLab, 91405 Orsay, France
| | - B Waidyawansa
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - Y Wang
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Wojtsekhowski
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - S Wood
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - X Yan
- Huangshan University, Huangshan, Anhui, 245041, China
| | - L Ye
- Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - Z Ye
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - C Yero
- Florida International University, Miami, Florida 33199, USA
| | - J Zhang
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - Y Zhao
- Stony Brook, State University of New York, New York 11794, USA
| | - P Zhu
- University of Science and Technology of China, Hefei, Anhui 230026, China
| |
Collapse
|
28
|
Benemerito I, Griffiths W, Allsopp J, Furnass W, Bhattacharya P, Li X, Marzo A, Wood S, Viceconti M, Narracott A. Delivering computationally-intensive digital patient applications to the clinic: An exemplar solution to predict femoral bone strength from CT data. Comput Methods Programs Biomed 2021; 208:106200. [PMID: 34107372 DOI: 10.1016/j.cmpb.2021.106200] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 05/19/2021] [Indexed: 06/12/2023]
Abstract
BACKGROUND AND OBJECTIVE Whilst fragility hip fractures commonly affect elderly people, often causing permanent disability or death, they are rarely addressed in advance through preventive techniques. Quantification of bone strength can help to identify subjects at risk, thus reducing the incidence of fractures in the population. In recent years, researchers have shown that finite element models (FEMs) of the hip joint, derived from computed tomography (CT) images, can predict bone strength more accurately than other techniques currently used in the clinic. The specialised hardware and trained personnel required to perform such analyses, however, limits the widespread adoption of FEMs in clinical contexts. In this manuscript we present CT2S (Computed Tomography To Strength), a system developed in collaboration between The University of Sheffield and Sheffield Teaching Hospitals, designed to streamline access to this complex workflow for clinical end-users. METHODS The system relies on XNAT and makes use of custom apps based on open source software. Available through a website, it allows doctors in the healthcare environment to benefit from FE based bone strength estimation without being exposed to the technical aspects, which are concealed behind a user-friendly interface. Clinicians request the analysis of CT scans of a patient through the website. Using XNAT functionality, the anonymised images are automatically transferred to the University research facility, where an operator processes them and estimates the bone strength through FEM using a combination of open source and commercial software. Following the analysis, the doctor is provided with the results in a structured report. RESULTS The platform, currently available for research purposes, has been deployed and fully tested in Sheffield, UK. The entire analysis requires processing times ranging from 3.5 to 8 h, depending on the available computational power. CONCLUSIONS The short processing time makes the system compatible with current clinical workflows. The use of open source software and the accurate description of the workflow given here facilitates the deployment in other centres.
Collapse
Affiliation(s)
- I Benemerito
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK.
| | - W Griffiths
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - J Allsopp
- Sheffield Teaching Hospital Foundation Trust, Sheffield, UK
| | - W Furnass
- Department of Computer Science, The University of Sheffield, UK
| | - P Bhattacharya
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - X Li
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - A Marzo
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Mechanical Engineering, The University of Sheffield, UK
| | - S Wood
- Sheffield Teaching Hospital Foundation Trust, Sheffield, UK
| | - M Viceconti
- Department of Industrial Engineering, Alma Mater Studiorium, University of Bologna, Italy; Medical Technology Lab, IRCSS Istituto Ortopedico Rizzoli, Bologna, Italy
| | - A Narracott
- INSIGNEO Institute for in silico Medicine, The University of Sheffield, UK; Department of Infection, Immunity & Cardiovascular Disease, The University of Sheffield, UK
| |
Collapse
|
29
|
Wyborn C, Montana J, Kalas N, Clement S, Davila F, Knowles N, Louder E, Balan M, Chambers J, Christel L, Forsyth T, Henderson G, Izquierdo Tort S, Lim M, Martinez‐Harms MJ, Merçon J, Nuesiri E, Pereira L, Pilbeam V, Turnhout E, Wood S, Ryan M. An agenda for research and action toward diverse and just futures for life on Earth. Conserv Biol 2021; 35:1086-1097. [PMID: 33244774 PMCID: PMC8359367 DOI: 10.1111/cobi.13671] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 10/14/2020] [Accepted: 11/20/2020] [Indexed: 06/11/2023]
Abstract
Decades of research and policy interventions on biodiversity have insufficiently addressed the dual issues of biodiversity degradation and social justice. New approaches are therefore needed. We devised a research and action agenda that calls for a collective task of revisiting biodiversity toward the goal of sustaining diverse and just futures for life on Earth. Revisiting biodiversity involves critically reflecting on past and present research, policy, and practice concerning biodiversity to inspire creative thinking about the future. The agenda was developed through a 2-year dialogue process that involved close to 300 experts from diverse disciplines and locations. This process was informed by social science insights that show biodiversity research and action is underpinned by choices about how problems are conceptualized. Recognizing knowledge, action, and ethics as inseparable, we synthesized a set of principles that help navigate the task of revisiting biodiversity. The agenda articulates 4 thematic areas for future research. First, researchers need to revisit biodiversity narratives by challenging conceptualizations that exclude diversity and entrench the separation of humans, cultures, economies, and societies from nature. Second, researchers should focus on the relationships between the Anthropocene, biodiversity, and culture by considering humanity and biodiversity as tied together in specific contexts. Third, researchers should focus on nature and economies by better accounting for the interacting structures of economic and financial systems as core drivers of biodiversity loss. Finally, researchers should enable transformative biodiversity research and action by reconfiguring relationships between human and nonhuman communities in and through science, policy, and practice. Revisiting biodiversity necessitates a renewed focus on dialogue among biodiversity communities and beyond that critically reflects on the past to channel research and action toward fostering just and diverse futures for human and nonhuman life on Earth.
Collapse
Affiliation(s)
- C. Wyborn
- Luc Hoffmann InstituteIUCN Conservation CentreRue Mauverney 28Gland1196Switzerland
- Institute for Water Futures, Fenner School of Environment and SocietyAustralian National UniversityCanberraACT0200Australia
| | - J. Montana
- School of Geography and the EnvironmentUniversity of OxfordSouth Parks RoadOxfordOX1 3QYU.K.
| | - N. Kalas
- Department of Environmental Systems ScienceETH ZürichUniversitätstrasse 8‐22Zürich8092Switzerland
| | - S. Clement
- Geography and PlanningUniversity of LiverpoolLiverpoolL69 3BXU.K.
| | - F. Davila
- Institute for Sustainable FuturesUniversity of Technology Sydney253 Jones StreetUltimoNSW2007Australia
| | - N. Knowles
- Department of Geography and Environmental ManagementUniversity of Waterloo200 University Ave WWaterlooONN2L 3G1Canada
| | - E. Louder
- School of Geography and DevelopmentUniversity of ArizonaENR2 Building, South 4th floor 1064 E. Lowell StreetTucsonAZ85721U.S.A.
| | - M. Balan
- The Forest WayNo 8, 2nd St, D P Nagar, KotturpuramChennaiTamil Nadu600085India
| | - J. Chambers
- Forest and Nature Conservation Policy GroupWageningen UniversityP.O. Box 47Wageningen6700 AAThe Netherlands
| | - L. Christel
- School of Politics and Government (EPyG)National University of San MartinAvenida 25 de Mayo 1021San MartínProvincia de Buenos Aires1650Argentina
| | - T. Forsyth
- Department of International DevelopmentLondon School of Economics and Political ScienceHoughton StreetLondonWC2A 2AEU.K
| | - G. Henderson
- Harry Ransom CenterThe University of Texas at AustinP.O. Drawer 7219, 300 W 21st StreetAustinTX78712U.S.A.
| | - S. Izquierdo Tort
- Institut des Sciences de la Forêt TempéréeUniversité du Québec en Outaouais58 rue PrincipaleRiponQCJ0V 1V0Canada
- Natura y Ecosistemas Mexicanos A.C.Plaza San Jacinto 23D, San Ángel, Álvaro ObregónMexico City01000Mexico
| | - M. Lim
- Centre for Environmental Law, Macquarie Law SchoolMacquarie University6 First WalkSydneyNSW2109Australia
| | - M. J. Martinez‐Harms
- Center for Applied Ecology and Sustainability (CAPES)Pontificia Universidad Católica de ChileSantiago, Avd. Libertador Bernardo O'Higgins 340SantiagoChile
| | - J. Merçon
- Instituto de Investigaciones en EducasiónUniversidad VeracruzanaPaseo 112, Nuevo JalapaXalapa‐Enríquez91193Mexico
| | - E. Nuesiri
- Social Science FacultyAfrican Leadership University (ALU)Powder Mill RoadPamplemousses21001Mauritius
| | - L. Pereira
- Stockholm Resilience CentreStockholm UniversityKräftriket 2BStockholmSE‐10691Sweden
- Copernicus Institute of Sustainable DevelopmentUtrecht UniversityPrincetonlaan 8aUtrecht3584 CBThe Netherlands
- Centre for Complex Systems in TransitionStellenbosch University19 Jonkershoek Rd, MostertsdriftStellenbosch7600South Africa
| | - V. Pilbeam
- Clear Horizon Consulting132B Gwynne StCremorneVIC3121Australia
| | - E. Turnhout
- Forest and Nature Conservation Policy GroupWageningen UniversityP.O. Box 47Wageningen6700 AAThe Netherlands
| | - S. Wood
- Future Earth1250 Guy St, MontrealQuebecONH3H 2L3Canada
| | - M. Ryan
- Luc Hoffmann InstituteIUCN Conservation CentreRue Mauverney 28Gland1196Switzerland
| |
Collapse
|
30
|
Wyborn C, Montana J, Kalas N, Clement S, Davila F, Knowles N, Louder E, Balan M, Chambers J, Christel L, Forsyth T, Henderson G, Izquierdo Tort S, Lim M, Martinez-Harms MJ, Merçon J, Nuesiri E, Pereira L, Pilbeam V, Turnhout E, Wood S, Ryan M. An agenda for research and action toward diverse and just futures for life on Earth. Conserv Biol 2021; 35:1086-1097. [PMID: 33244774 DOI: 10.13140/rg.2.2.12086.52804/2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 10/14/2020] [Accepted: 11/20/2020] [Indexed: 05/18/2023]
Abstract
Decades of research and policy interventions on biodiversity have insufficiently addressed the dual issues of biodiversity degradation and social justice. New approaches are therefore needed. We devised a research and action agenda that calls for a collective task of revisiting biodiversity toward the goal of sustaining diverse and just futures for life on Earth. Revisiting biodiversity involves critically reflecting on past and present research, policy, and practice concerning biodiversity to inspire creative thinking about the future. The agenda was developed through a 2-year dialogue process that involved close to 300 experts from diverse disciplines and locations. This process was informed by social science insights that show biodiversity research and action is underpinned by choices about how problems are conceptualized. Recognizing knowledge, action, and ethics as inseparable, we synthesized a set of principles that help navigate the task of revisiting biodiversity. The agenda articulates 4 thematic areas for future research. First, researchers need to revisit biodiversity narratives by challenging conceptualizations that exclude diversity and entrench the separation of humans, cultures, economies, and societies from nature. Second, researchers should focus on the relationships between the Anthropocene, biodiversity, and culture by considering humanity and biodiversity as tied together in specific contexts. Third, researchers should focus on nature and economies by better accounting for the interacting structures of economic and financial systems as core drivers of biodiversity loss. Finally, researchers should enable transformative biodiversity research and action by reconfiguring relationships between human and nonhuman communities in and through science, policy, and practice. Revisiting biodiversity necessitates a renewed focus on dialogue among biodiversity communities and beyond that critically reflects on the past to channel research and action toward fostering just and diverse futures for human and nonhuman life on Earth.
Collapse
Affiliation(s)
- C Wyborn
- Luc Hoffmann Institute, IUCN Conservation Centre, Rue Mauverney 28, Gland, 1196, Switzerland
- Institute for Water Futures, Fenner School of Environment and Society, Australian National University, Canberra, ACT, 0200, Australia
| | - J Montana
- School of Geography and the Environment, University of Oxford, South Parks Road, Oxford, OX1 3QY, U.K
| | - N Kalas
- Department of Environmental Systems Science, ETH Zürich, Universitätstrasse 8-22, Zürich, 8092, Switzerland
| | - S Clement
- Geography and Planning, University of Liverpool, Liverpool, L69 3BX, U.K
| | - F Davila
- Institute for Sustainable Futures, University of Technology Sydney, 253 Jones Street, Ultimo, NSW, 2007, Australia
| | - N Knowles
- Department of Geography and Environmental Management, University of Waterloo, 200 University Ave W, Waterloo, ON, N2L 3G1, Canada
| | - E Louder
- School of Geography and Development, University of Arizona, ENR2 Building, South 4th floor 1064 E. Lowell Street, Tucson, AZ, 85721, U.S.A
| | - M Balan
- The Forest Way, No 8, 2nd St, D P Nagar, Kotturpuram, Chennai, Tamil Nadu, 600085, India
| | - J Chambers
- Forest and Nature Conservation Policy Group, Wageningen University, P.O. Box 47, Wageningen, 6700 AA, The Netherlands
| | - L Christel
- School of Politics and Government (EPyG), National University of San Martin, Avenida 25 de Mayo 1021, San Martín, Provincia de Buenos Aires, 1650, Argentina
| | - T Forsyth
- Department of International Development, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, U.K
| | - G Henderson
- Harry Ransom Center, The University of Texas at Austin, P.O. Drawer 7219, 300 W 21st Street, Austin, TX, 78712, U.S.A
| | - S Izquierdo Tort
- Institut des Sciences de la Forêt Tempérée, Université du Québec en Outaouais, 58 rue Principale, Ripon, QC, J0V 1V0, Canada
- Natura y Ecosistemas Mexicanos A.C., Plaza San Jacinto 23D, San Ángel, Álvaro Obregón, Mexico City, 01000, Mexico
| | - M Lim
- Centre for Environmental Law, Macquarie Law School, Macquarie University, 6 First Walk, Sydney, NSW, 2109, Australia
| | - M J Martinez-Harms
- Center for Applied Ecology and Sustainability (CAPES), Pontificia Universidad Católica de Chile, Santiago, Avd. Libertador Bernardo O'Higgins 340, Santiago, Chile
| | - J Merçon
- Instituto de Investigaciones en Educasión, Universidad Veracruzana, Paseo 112, Nuevo Jalapa, Xalapa-Enríquez, 91193, Mexico
| | - E Nuesiri
- Social Science Faculty, African Leadership University (ALU), Powder Mill Road, Pamplemousses, 21001, Mauritius
| | - L Pereira
- Stockholm Resilience Centre, Stockholm University, Kräftriket 2B, Stockholm, SE-10691, Sweden
- Copernicus Institute of Sustainable Development, Utrecht University, Princetonlaan 8a, Utrecht, 3584 CB, The Netherlands
- Centre for Complex Systems in Transition, Stellenbosch University, 19 Jonkershoek Rd, Mostertsdrift, Stellenbosch, 7600, South Africa
| | - V Pilbeam
- Clear Horizon Consulting, 132B Gwynne St, Cremorne, VIC, 3121, Australia
| | - E Turnhout
- Forest and Nature Conservation Policy Group, Wageningen University, P.O. Box 47, Wageningen, 6700 AA, The Netherlands
| | - S Wood
- Future Earth, 1250 Guy St, Montreal, Quebec, ON, H3H 2L3, Canada
| | - M Ryan
- Luc Hoffmann Institute, IUCN Conservation Centre, Rue Mauverney 28, Gland, 1196, Switzerland
| |
Collapse
|
31
|
Abstract
The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with up to 80% of patients with advanced disease developing bone metastases (BM). The proportion is also substantial in advanced lung cancer (20%-40%). Because of the high prevalence of cancers of the breast, prostate and lung, these cancers account for more than 80% of cases of metastatic bone disease occurring in solid tumours. Metastatic bone disease is associated with greatly increased bone resorption by osteoclasts, leading to moderate to severe pain and other skeletal complications, with major impact on quality of life (QoL). Skeletal Related Events (SREs) have been defined as: pathological long bone or vertebral fractures; spinal cord compression; need for radiation for pain relief or to prevent fracture/spinal cord compression, need for surgery to bone and hypercalcaemia. More recently, Symptomatic Skeletal Events (SSEs) have been defined to monitor QoL. Although there are currently no curative treatments for metastatic bone disease, patients with breast or prostate cancer and BM are now surviving for several years and sometimes longer, and prevention of SREs is the key aim to optimization of QoL. Since their discovery 50 years ago and their introduction more than 30 years ago into the field of metastatic bone disease, a range of oral and intravenous bisphosphonate drugs have made a major contribution to prevention of SREs. Large trials have clearly demonstrated the clinical value of different bisphosphonate-based drugs (including the oral drugs ibandronate and clodronate and intravenous agents such as zoledronate and pamidronate), in treatment of hypercalcaemia of malignancy and the reduction of SREs and SSEs in a range of cancers. Despite the success of denosumab in reducing osteolysis, bisphosphonates also remain mainstay drugs for treatment of metastatic bone disease. Recognizing the 50th Anniversary of the discovery of bisphosphonates, this review focuses on their continuing value in BM treatment and their future potential, for example in providing a bone-targeting vehicle for cytotoxic drugs.
Collapse
Affiliation(s)
- S D'Oronzo
- Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, P.za Giulio Cesare, 11, 70124 Bari, Italy
| | - S Wood
- Department of Oncology and Metabolism, The Medical School, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.
| | - J E Brown
- Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Whitham Rd, Broomhill, Sheffield S10 2SJ, UK
| |
Collapse
|
32
|
Lopez‐Girona A, Groocock L, Mo Z, Narla RK, Janardhanan P, Wood S, Mendy D, Barnes L, Peng S, Jankeel D, Fontanillo C, Carrancio S, Hansen J. CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.144_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A Lopez‐Girona
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - L Groocock
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - Z Mo
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - R. K Narla
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - P Janardhanan
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - S Wood
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - D Mendy
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - L Barnes
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - S Peng
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - D Jankeel
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - C Fontanillo
- Bristol Myers Squibb, Informatics and Predictive Sciences, Princeton New Jersey USA
| | - S Carrancio
- Bristol Myers Squibb, Oncogenesis Therapeutic Research Center, Princeton New Jersey USA
| | - J Hansen
- Bristol Myers Squibb, Small Molecule Drug Discovery, Princeton New Jersey USA
| |
Collapse
|
33
|
Clark EM, Garner J, Wood S. Commercial weight management programmes for patients living with overweight or obesity prior to elective orthopaedic surgery: an evidence review. J Public Health (Oxf) 2021; 44:417-427. [PMID: 33550385 DOI: 10.1093/pubmed/fdaa253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 11/18/2020] [Accepted: 12/11/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Increased body mass index is associated with increased operative risk during elective joint replacement surgery. Commercial weight management programmes are designed to achieve weight loss. It is not known whether commercial weight management programmes are effective at achieving weight loss in patients awaiting planned hip or knee replacement surgery, or whether achieving significant planned weight loss prior to surgery is associated with changes in surgical outcome. METHODS A systematic literature search of seven databases was conducted. Reference lists and grey literature were searched, including commercial weight management programme and medical association websites. Four relevant primary interventional studies were identified. RESULTS There is weak, low-quality evidence from four small studies, of which three demonstrated that commercial weight management programmes initiated between 3 and 6 months prior to elective joint replacement surgery are associated with a statistically significant weight loss and body mass index reduction. There is a weak evidence from two studies that peri- and post-operative complications are similar between control and commercial weight management programme groups. CONCLUSION There is a paucity of studies investigating commercial weight management programmes aiming to reduce weight in patients living with overweight or obesity awaiting total joint replacement. Further, high-quality research is urgently needed.
Collapse
Affiliation(s)
- E M Clark
- Public Health Wales, Capital Quarter 2, Cardiff, CF10 4BZ, Wales
| | - J Garner
- Public Health Wales, Capital Quarter 2, Cardiff, CF10 4BZ, Wales
| | - S Wood
- Public Health Wales, Cardiff, CF14 4HH, Wales
| |
Collapse
|
34
|
Bubak M, Czechowicz K, Gubała T, Hose DR, Kasztelnik M, Malawski M, Meizner J, Nowakowski P, Wood S. The EurValve model execution environment. Interface Focus 2021; 11:20200006. [PMID: 33343876 DOI: 10.1098/rsfs.2020.0006] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/23/2020] [Indexed: 01/14/2023] Open
Abstract
The goal of this paper is to present a dedicated high-performance computing (HPC) infrastructure which is used in the development of a so-called reduced-order model (ROM) for simulating the outcomes of interventional procedures which are contemplated in the treatment of valvular heart conditions. Following a brief introduction to the problem, the paper presents the design of a model execution environment, in which representative cases can be simulated and the parameters of the ROM fine-tuned to enable subsequent deployment of a decision support system without further need for HPC. The presentation of the system is followed by information concerning its use in processing specific patient cases in the context of the EurValve international collaboration.
Collapse
Affiliation(s)
- M Bubak
- Department of Computer Science, AGH University of Science and Technology, Kraków, Poland.,ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - K Czechowicz
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - T Gubała
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - D R Hose
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - M Kasztelnik
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - M Malawski
- Department of Computer Science, AGH University of Science and Technology, Kraków, Poland.,ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - J Meizner
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - P Nowakowski
- ACC Cyfronet AGH University of Science and Technology, Kraków, Poland.,Sano Centre for Computational Medicine, Kraków, Poland
| | - S Wood
- Medical Physics and Clinical Engineering, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| |
Collapse
|
35
|
Tee HS, Waite D, Payne L, Middleditch M, Wood S, Handley KM. Tools for successful proliferation: diverse strategies of nutrient acquisition by a benthic cyanobacterium. ISME J 2020; 14:2164-2178. [PMID: 32424245 PMCID: PMC7367855 DOI: 10.1038/s41396-020-0676-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Revised: 04/23/2020] [Accepted: 05/01/2020] [Indexed: 12/28/2022]
Abstract
Freshwater cyanobacterial blooms have increased worldwide, channeling organic carbon into these systems, and threatening animal health through the production of cyanotoxins. Both toxic and nontoxic Microcoleus proliferations usually occur when there are moderate concentrations of dissolved inorganic nitrogen, but when phosphorus is scarce. In order to understand how Microcoleus establishes thick biofilms (or mats) on riverbeds under phosphorus-limiting conditions, we collected Microcoleus-dominated biofilms over a 19-day proliferation event for proteogenomics. A single pair of nitrogen-dependent Microcoleus species were consistently present in relatively high abundance, although each followed a unique metabolic trajectory. Neither possessed anatoxin gene clusters, and only very low concentrations of anatoxins (~2 µg kg-1) were detected, likely originating from rarer Microcoleus species also present. Proteome allocations were dominated by photosynthesizing cyanobacteria and diatoms, and data indicate biomass was actively recycled by Bacteroidetes and Myxococcales. Microcoleus likely acquired nutrients throughout the proliferation event by uptake of nitrate, urea, and inorganic and organic phosphorus. Both species also harbored genes that could be used for inorganic phosphate solubilization with pyrroloquinoline quinone cofactors produced by cohabiting Proteobacteria. Results indicate that Microcoleus are equipped with diverse mechanisms for nitrogen and phosphorus acquisition, enabling them to proliferate and out-compete others in low-phosphorus waters.
Collapse
Affiliation(s)
- H S Tee
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - D Waite
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - L Payne
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - M Middleditch
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - S Wood
- Cawthron Institute, Nelson, New Zealand
| | - K M Handley
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.
| |
Collapse
|
36
|
Wood S, Conrad D, Schwalbe N. Washington’s State Innovation Models (SIM) Project: Effects of Primary Care and Behavioral Health Integration on Participating Organizations. Health Serv Res 2020. [DOI: 10.1111/1475-6773.13380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Affiliation(s)
- S. Wood
- University of Washington Seattle WA United States
| | - D. Conrad
- University of Washington Seattle WA United States
| | - N. Schwalbe
- University of Washington Seattle WA United States
| |
Collapse
|
37
|
Francis N, Penna M, Carter F, Mortensen NJ, Hompes R, Bandyopadhyay D, Black J, Campbell K, Chadwick M, Chase K, Chitsabesen P, Coleman M, Dalton S, Doeve J, Hendrickse C, Katory M, Knol J, Lee L, McArthur D, Miles T, Miskovic D, Ng P, Nicol D, Samad A, Talwar A, Kochupapy RT, Theobald I, Wegstapel H, West N, Wood S, Wynn G, Ziyaie D. Development and early outcomes of the national training initiative for transanal total mesorectal excision in the UK. Colorectal Dis 2020; 22:756-767. [PMID: 32065425 DOI: 10.1111/codi.15022] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Accepted: 02/11/2020] [Indexed: 12/17/2022]
Abstract
AIM Transanal total mesorectal excision (TaTME) has attracted substantial interest amongst colorectal surgeons but its technical challenges may underlie the early reports of visceral injuries and oncological concerns. The aim of this study was to report on the feasibility, development and the outcome of the national pilot training initiative for TaTME-UK. METHODS TaTME-UK was successfully launched in September 2017 in partnership with the healthcare industry and endorsed by the Association of Coloproctology of Great Britain and Ireland. This multi-modal training curriculum consisted of three phases: (i) set-up; (ii) selection of pilot sites; and (iii) formal proctorship programme. Bespoke Global Assessment Scoring (GAS) forms were designed and completed by both trainees and mentors. Data were collected on patient demographics, tumour characteristics and perioperative clinical and histological outcomes. RESULTS Twenty-four proctored cases were performed by 10 colorectal surgeons from five selected pilot sites. Median operative time was 331 ± 90 (195-610) min which was reduced to 283 ± 62 (195-340) min in the final case. Independent performance (GAS score of 5) was achieved for most operative steps by case 5. There was one conversion (4.2%), but no visceral injuries. Pathological data confirmed no bowel perforation and intact quality of the mesorectal TME specimens with clear distal margin in all cases and circumferential margins in 23/24 cases (96%). CONCLUSION This exploratory study demonstrates acceptable early outcomes in a small cohort suggesting that a competency-based multi-modal training programme for TaTME can be feasible and safe to implement at a national level.
Collapse
Affiliation(s)
- N Francis
- Department of Colorectal Surgery, Yeovil District Hospital Foundation Trust, Yeovil, UK.,Division of Surgery and Interventional Science, University College London, London, UK.,Faculty of Science, University of Bath, Bath, UK
| | - M Penna
- Department of Colorectal Surgery, Churchill Hospital, University Hospitals of Oxford, Oxford, UK.,Department of Surgery and Cancer, Imperial College London, London, UK
| | - F Carter
- South West Surgical Training Network c.i.c., Yeovil, UK
| | - N J Mortensen
- Department of Colorectal Surgery, Churchill Hospital, University Hospitals of Oxford, Oxford, UK
| | - R Hompes
- Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Khalil A, Sotiriadis A, Chaoui R, da Silva Costa F, D'Antonio F, Heath PT, Jones C, Malinger G, Odibo A, Prefumo F, Salomon LJ, Wood S, Ville Y. ISUOG Practice Guidelines: role of ultrasound in congenital infection. Ultrasound Obstet Gynecol 2020; 56:128-151. [PMID: 32400006 DOI: 10.1002/uog.21991] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 01/27/2020] [Indexed: 06/11/2023]
Affiliation(s)
- A Khalil
- Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, University of London, London, UK
- Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK
| | - A Sotiriadis
- Second Department of Obstetrics and Gynecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - R Chaoui
- Center for Prenatal Diagnosis and Human Genetics, Berlin, Germany
| | - F da Silva Costa
- Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, São Paulo, Brazil
- Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia
| | - F D'Antonio
- Women's Health and Perinatology Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway
- Department of Obstetrics and Gynecology, University Hospital of Northern Norway, Tromsø, Norway
| | - P T Heath
- Paediatric Infectious Diseases Research Group and Vaccine Institute, St George's University of London and St George's University Hospitals NHS Trust, London, UK
| | - C Jones
- Faculty of Medicine and Institute for Life Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - G Malinger
- Ultrasound Unit, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - A Odibo
- Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - F Prefumo
- Division of Obstetrics and Gynecology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - L J Salomon
- Department of Obstetrics and Fetal Medicine, Hopital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris, France
| | | | - Y Ville
- Department of Obstetrics and Fetal Medicine, Hopital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris Descartes University, Paris, France
| |
Collapse
|
39
|
Mehawed G, Tariq A, Saadat P, Joshi A, Roberts M, Perera M, Rhee H, Yeates A, Mckenzie I, Munns J, Chung E, Heathcote P, Preston J, Lawson M, Wood S, Gustafson S, Miles K, Vela I. Correlation between hybrid PSMA PET MRI and histopathology at radical prostatectomy. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)32890-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
40
|
Joshi A, Roberts MJ, Perera M, Williams E, Rhee H, Pryor D, Lehman M, Heathcote P, Wood S, Coucher J, Gustafson S, Miles K, Vela I. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clin Exp Metastasis 2020; 37:551-560. [PMID: 32519046 DOI: 10.1007/s10585-020-10043-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 06/05/2020] [Indexed: 11/30/2022]
Abstract
Prospective evidence for the clinical role and efficacy of prostate specific membrane antigen (PSMA) positron emission tomography (PET)/magnetic resonance imaging (MRI) combining MRI characterization and localization of lesions with PET avidity in comparison to conventional imaging is limited. In a prospective clinical trial, we aimed to evaluate the diagnostic yield and therapeutic impact of PSMA PET/MRI in men with biochemical recurrence (BCR) following curative therapy. A single-centre, prospective clinical trial at the Princess Alexandra Hospital recruited 30 patients with BCR. Patients underwent PSMA PET/MRI and concurrent conventional CT chest, abdomen, pelvis and whole-body bone scan. Biopsy was performed when safety possible for histological correlation of identified lesions. Clinical efficacy and impact of PSMA PET findings were evaluated. 30 patients with BCR were recruited (median PSA 0.69 ng/ml). PSMA avid lesions were present in 21 patients (70%). 23 patients were previously treated with definitive surgery, 6 patients received external beam radiotherapy and 1 patient had low dose rate brachytherapy. A total of 8 of 9 lesions biopsied were positive (88.9% histological correlation). PSMA PET/MRI detected local recurrence (p = 0.005) and pelvic lesions (p = 0.06) more accurately than conventional imaging. PSMA PET/MRI may be useful in staging men with biochemical recurrence, especially when PSA is low. Our data demonstrates a high detection rate, especially for locally recurrent disease, and highlights the role of this modality when PSA is low. This modality has the potential to significantly improve prostate cancer detection and may have implications for earlier salvage treatment, avoidance of futile local therapy and change patient management to lead to improved outcomes.
Collapse
Affiliation(s)
- A Joshi
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia.,Faculty of Medicine, The University of Queensland, Brisbane, Australia
| | - M J Roberts
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Faculty of Medicine, The University of Queensland, Brisbane, Australia
| | - M Perera
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | - E Williams
- Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia
| | - H Rhee
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia
| | - D Pryor
- Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia
| | - M Lehman
- Department of Radiation Oncology, Princess Alexandra Hospital, Brisbane, Australia
| | - P Heathcote
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
| | - S Wood
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.,Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia
| | - J Coucher
- Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia
| | - S Gustafson
- Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia
| | - K Miles
- Department of Nuclear Medicine, Princess Alexandra Hospital, Brisbane, Australia
| | - I Vela
- Department of Urology, Princess Alexandra Hospital, Brisbane, Australia. .,Australian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, QLD, Australia. .,Faculty of Medicine, The University of Queensland, Brisbane, Australia.
| |
Collapse
|
41
|
Wood S, Hyrich K, Verstappen S, Steinke D. AB1203 INVESTIGATING THE VIEWS OF COMMUNITY PHARMACISTS ON THEIR ROLE IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Medicines optimisation is essential in the long-term management of rheumatoid arthritis (RA), particularly when considering combinations of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Community pharmacists are ideally placed to optimise medicines use including monitoring side effects, counselling on dose and frequency and improving medicines adherence; however, in some countries, such as the UK, there are currently no community pharmacy services that address csDMARD use and little is known about the role community pharmacists play in managing RA as a long-term condition.Objectives:The objectives of this qualitative study were to understand community pharmacists’ views of their training, knowledge and current role in the management of RA.Methods:We conducted 9 semi-structured, face-to-face or telephone interviews with community pharmacists based in the UK; all were transcribed verbatim. A topic guide, used to inform the interviews, covered four key areas: 1) knowledge and training, 2) pharmacological management 3) patients and services, 4) potential role. The transcriptions were then imported into NVivo for thematic analysis. A coding framework was developed from continual emerging themes and applied to the transcripts.Results:Five male/4 female participants, the median age was 39 years (range 27 to 42) with a median number of years qualified as a pharmacist of 12 years (range 5 to 20) were included. The participants covered a range of roles including: pharmacist non-manager, pharmacist manager, locum pharmacist, superintendent pharmacist and relief pharmacist.In assessing the current role of community pharmacists, 4 main themes were identified: (1) access to information about the patient’s condition as a barrier, (2) their lack of knowledge in the management of RA, (3) providing practical advice about taking csDMARDs, and (4) exploring the reasons for non-adherence before taking further action. In assessing the potential role of community pharmacists, a further 2 themes were identified: improving access to information about the patient’s condition before the current role can be increased and other barriers to an additional role, including time and funding.In the theme ‘access to information as a barrier’ the most common point made was about the lack of information available to pharmacists on the individual indication for medicines. Pharmacists said this posed a barrier both to current practice and their potential role. No participants suggested the potential for an additional service specifically for RA, but some suggested that current services could be expanded to include RA as a target group. Participants discussed side effect counselling and ensuring access to medicines in detail with patients, but only 2 briefly mentioned discussing the benefits of csDMARDs.Conclusion:This is the first in-depth exploration of the perspectives of community pharmacists on the management of RA in community pharmacy. This study has highlighted several important barriers both environmental and personal including time, education and resources that, if addressed, could allow community pharmacists to play a greater role in the management of RA.Disclosure of Interests:Sarah Wood: None declared, Kimme Hyrich Grant/research support from: Pfizer, UCB, BMS, Speakers bureau: Abbvie, Suzanne Verstappen Grant/research support from: BMS, Consultant of: Celltrion, Speakers bureau: Pfizer, Douglas Steinke: None declared
Collapse
|
42
|
Cruz-Torres R, Nguyen D, Hauenstein F, Schmidt A, Li S, Abrams D, Albataineh H, Alsalmi S, Androic D, Aniol K, Armstrong W, Arrington J, Atac H, Averett T, Ayerbe Gayoso C, Bai X, Bane J, Barcus S, Beck A, Bellini V, Benmokhtar F, Bhatt H, Bhetuwal D, Biswas D, Blyth D, Boeglin W, Bulumulla D, Camsonne A, Castellanos J, Chen JP, Cohen EO, Covrig S, Craycraft K, Dongwi B, Duer M, Duran B, Dutta D, Fuchey E, Gal C, Gautam TN, Gilad S, Gnanvo K, Gogami T, Golak J, Gomez J, Gu C, Habarakada A, Hague T, Hansen O, Hattawy M, Hen O, Higinbotham DW, Hughes E, Hyde C, Ibrahim H, Jian S, Joosten S, Kamada H, Karki A, Karki B, Katramatou AT, Keppel C, Khachatryan M, Khachatryan V, Khanal A, King D, King P, Korover I, Kutz T, Lashley-Colthirst N, Laskaris G, Li W, Liu H, Liyanage N, Markowitz P, McClellan RE, Meekins D, Mey-Tal Beck S, Meziani ZE, Michaels R, Mihovilovič M, Nelyubin V, Nuruzzaman N, Nycz M, Obrecht R, Olson M, Ou L, Owen V, Pandey B, Pandey V, Papadopoulou A, Park S, Patsyuk M, Paul S, Petratos GG, Piasetzky E, Pomatsalyuk R, Premathilake S, Puckett AJR, Punjabi V, Ransome R, Rashad MNH, Reimer PE, Riordan S, Roche J, Sargsian M, Santiesteban N, Sawatzky B, Segarra EP, Schmookler B, Shahinyan A, Širca S, Skibiński R, Sparveris N, Su T, Suleiman R, Szumila-Vance H, Tadepalli AS, Tang L, Tireman W, Topolnicki K, Tortorici F, Urciuoli G, Weinstein LB, Witała H, Wojtsekhowski B, Wood S, Ye ZH, Ye ZY, Zhang J. Probing Few-Body Nuclear Dynamics via ^{3}H and ^{3}He (e,e^{'}p)pn Cross-Section Measurements. Phys Rev Lett 2020; 124:212501. [PMID: 32530643 DOI: 10.1103/physrevlett.124.212501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 03/12/2020] [Accepted: 04/30/2020] [Indexed: 06/11/2023]
Abstract
We report the first measurement of the (e,e^{'}p) three-body breakup reaction cross sections in helium-3 (^{3}He) and tritium (^{3}H) at large momentum transfer [⟨Q^{2}⟩≈1.9 (GeV/c)^{2}] and x_{B}>1 kinematics, where the cross section should be sensitive to quasielastic (QE) scattering from single nucleons. The data cover missing momenta 40≤p_{miss}≤500 MeV/c that, in the QE limit with no rescattering, equals the initial momentum of the probed nucleon. The measured cross sections are compared with state-of-the-art ab initio calculations. Overall good agreement, within ±20%, is observed between data and calculations for the full p_{miss} range for ^{3}H and for 100≤p_{miss}≤350 MeV/c for ^{3}He. Including the effects of rescattering of the outgoing nucleon improves agreement with the data at p_{miss}>250 MeV/c and suggests contributions from charge-exchange (SCX) rescattering. The isoscalar sum of ^{3}He plus ^{3}H, which is largely insensitive to SCX, is described by calculations to within the accuracy of the data over the entire p_{miss} range. This validates current models of the ground state of the three-nucleon system up to very high initial nucleon momenta of 500 MeV/c.
Collapse
Affiliation(s)
- R Cruz-Torres
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - D Nguyen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- University of Education, Hue University, Hue City, Vietnam
| | - F Hauenstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Schmidt
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Li
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - D Abrams
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - H Albataineh
- Texas A & M University, Kingsville, Texas 78363, USA
| | - S Alsalmi
- King Saud University, Riyadh 11451, Kingdom of Saudi Arabia
| | - D Androic
- University of Zagreb, 10000 Zagreb, Croatia
| | - K Aniol
- California State University, Los Angeles, California 90032, USA
| | - W Armstrong
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Arrington
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - H Atac
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - T Averett
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - C Ayerbe Gayoso
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - X Bai
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - J Bane
- University of Tennessee, Knoxville, Tennessee 37966, USA
| | - S Barcus
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - A Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Bellini
- INFN Sezione di Catania, 95123 Catania, Italy
| | - F Benmokhtar
- Duquesne University, Pittsburgh, Pennsylvania 15282, USA
| | - H Bhatt
- Mississippi State University, Mississippi 39762, USA
| | - D Bhetuwal
- Mississippi State University, Mississippi 39762, USA
| | - D Biswas
- Hampton University, Hampton, Virginia 23669, USA
| | - D Blyth
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - W Boeglin
- Florida International University, Miami, Florida 33199, USA
| | - D Bulumulla
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - A Camsonne
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - J Castellanos
- Florida International University, Miami, Florida 33199, USA
| | - J-P Chen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E O Cohen
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - S Covrig
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - K Craycraft
- University of Tennessee, Knoxville, Tennessee 37966, USA
| | - B Dongwi
- Hampton University, Hampton, Virginia 23669, USA
| | - M Duer
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - B Duran
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - D Dutta
- Mississippi State University, Mississippi 39762, USA
| | - E Fuchey
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - C Gal
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T N Gautam
- Hampton University, Hampton, Virginia 23669, USA
| | - S Gilad
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - K Gnanvo
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - T Gogami
- Tohoku University, Sendai, Miyagi 980-8577, Japan
| | - J Golak
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - J Gomez
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - C Gu
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A Habarakada
- Hampton University, Hampton, Virginia 23669, USA
| | - T Hague
- Kent State University, Kent, Ohio 44240, USA
| | - O Hansen
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Hattawy
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - O Hen
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | - E Hughes
- Columbia University, New York, New York 10027, USA
| | - C Hyde
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Ibrahim
- Cairo University, 12613 Cairo, Egypt
| | - S Jian
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - S Joosten
- Temple University, Philadelphia, Pennsylvania 19122, USA
| | - H Kamada
- Department of Physics, Faculty of Engineering, Kyushu Institute of Technology, Kitakyushu 804-8550, Japan
| | - A Karki
- Mississippi State University, Mississippi 39762, USA
| | - B Karki
- Ohio University, Athens, Ohio 45701, USA
| | | | - C Keppel
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Khachatryan
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - V Khachatryan
- Stony Brook, State University of New York, New York 11794, USA
| | - A Khanal
- Florida International University, Miami, Florida 33199, USA
| | - D King
- Syracuse University, Syracuse, New York 13244, USA
| | - P King
- Ohio University, Athens, Ohio 45701, USA
| | - I Korover
- Nuclear Research Center-Negev, Beer-Sheva, Israel
| | - T Kutz
- Stony Brook, State University of New York, New York 11794, USA
| | | | - G Laskaris
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - W Li
- University of Regina, Regina, SK S4S 0A2, Canada
| | - H Liu
- Columbia University, New York, New York 10027, USA
| | - N Liyanage
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - P Markowitz
- Florida International University, Miami, Florida 33199, USA
| | | | - D Meekins
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - S Mey-Tal Beck
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z-E Meziani
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
- Columbia University, New York, New York 10027, USA
| | - R Michaels
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - M Mihovilovič
- University of Ljubljana, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, Jožef Stefan Institute, Ljubljana, Slovenia
- Institut für Kernphysik, Johannes Gutenberg-Universität Mainz, DE-55128 Mainz, Germany
| | - V Nelyubin
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - N Nuruzzaman
- Hampton University, Hampton, Virginia 23669, USA
| | - M Nycz
- Kent State University, Kent, Ohio 44240, USA
| | - R Obrecht
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - M Olson
- Saint Norbert College, De Pere, Wisconsin 54115, USA
| | - L Ou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - V Owen
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | - B Pandey
- Hampton University, Hampton, Virginia 23669, USA
| | - V Pandey
- Department of Physics, University of Florida, Gainesville, Florida 32611, USA
| | - A Papadopoulou
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Park
- Stony Brook, State University of New York, New York 11794, USA
| | - M Patsyuk
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - S Paul
- The College of William and Mary, Williamsburg, Virginia 23185, USA
| | | | - E Piasetzky
- School of Physics and Astronomy, Tel Aviv University, Tel Aviv 69978, Israel
| | - R Pomatsalyuk
- Institute of Physics and Technology, Kharkov 61108, Ukraine
| | - S Premathilake
- University of Virginia, Charlottesville, Virginia 22904, USA
| | - A J R Puckett
- University of Connecticut, Storrs, Connecticut 06269, USA
| | - V Punjabi
- Norfolk State University, Norfolk, Virginia 23504, USA
| | - R Ransome
- Rutgers University, New Brunswick, New Jersey 08901, USA
| | - M N H Rashad
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - P E Reimer
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - S Riordan
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J Roche
- Ohio University, Athens, Ohio 45701, USA
| | - M Sargsian
- Florida International University, Miami, Florida 33199, USA
| | - N Santiesteban
- University of New Hampshire, Durham, New Hampshire 03824, USA
| | - B Sawatzky
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - E P Segarra
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - B Schmookler
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - A Shahinyan
- Yerevan Physics Institute, 0036 Yerevan, Armenia
| | - S Širca
- University of Ljubljana, 1000 Ljubljana, Slovenia
- Faculty of Mathematics and Physics, Jožef Stefan Institute, SI-1000, Ljubljana, Slovenia
| | - R Skibiński
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - N Sparveris
- Columbia University, New York, New York 10027, USA
| | - T Su
- Kent State University, Kent, Ohio 44240, USA
| | - R Suleiman
- Jefferson Lab, Newport News, Virginia 23606, USA
| | | | - A S Tadepalli
- Rutgers University, New Brunswick, New Jersey 08901, USA
| | - L Tang
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - W Tireman
- Northern Michigan University, Marquette, Michigan 49855, USA
| | - K Topolnicki
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | - F Tortorici
- INFN Sezione di Catania, 95123 Catania, Italy
| | | | - L B Weinstein
- Old Dominion University, Norfolk, Virginia 23529, USA
| | - H Witała
- M. Smoluchowski Institute of Physics, Jagiellonian University, PL-30348 Kraków, Poland
| | | | - S Wood
- Jefferson Lab, Newport News, Virginia 23606, USA
| | - Z H Ye
- Physics Division, Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - Z Y Ye
- University of Illinois-Chicago, Chicago, Illinois 60607, USA
| | - J Zhang
- Stony Brook, State University of New York, New York 11794, USA
| |
Collapse
|
43
|
D'Oronzo S, Lovero D, Palmirotta R, Cafforio P, Brown J, Wood S, Cives M, Tucci M, Stucci L, Coleman R, Silvestris F. 30P In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
44
|
Cotton SM, Berk M, Watson A, Wood S, Allott K, Bartholomeusz CF, Bortolasci CC, Walder K, O'Donoghue B, Dean OM, Chanen A, Amminger GP, McGorry PD, Burnside A, Uren J, Ratheesh A, Dodd S. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis. Trials 2019; 20:658. [PMID: 31779696 PMCID: PMC6883553 DOI: 10.1186/s13063-019-3786-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 10/09/2019] [Indexed: 12/13/2022] Open
Abstract
Background First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medications is suboptimal, particularly for negative and cognitive symptoms, and more efficacious and benign treatments are needed. Previous studies have shown that the antioxidant amino acid N-acetylcysteine (NAC) reduces negative symptoms and improves functioning in chronic schizophrenia and bipolar disorder. Research is scarce as to whether NAC is beneficial earlier in the course of illness. The primary aim of this study is to determine the efficacy of treatment with adjunctive NAC (2 g/day for 26 weeks) compared with placebo to improve psychiatric symptoms in young people experiencing FEP. Secondary aims are to explore the neurobiological mechanisms underpinning NAC and how they relate to various clinical and functional outcomes at 26- and 52-week follow-ups. Methods/design ENACT is a 26-week, randomised controlled trial of adjunctive NAC versus placebo, with a 26-week non-treatment follow-up period, for FEP. We will be recruiting 162 young people aged 15–25 years who have recently presented to, and are being treated at, the Early Psychosis Prevention and Intervention Centre, Melbourne, Australia. The primary outcome is the Total Score on the Positive and Negative Syndrome Scale which will be administered at baseline, and weeks 4, 8, 12, 26 (primary endpoint), and 52 (end of study). Secondary outcomes include: symptomatology, functioning, quality of life, neurocognition, blood-derived measures of: inflammation, oxidative and nitrosative stress, and magnetic resonance spectroscopy measures of glutathione concentration. Discussion Targeted drug development for FEP to date has generally not involved the exploration of neuroprotective agents. This study has the potential to offer a new, safe, and efficacious treatment for people with FEP, leading to better treatment outcomes. Additionally, the neuroprotective dimension of this study may lead to a better long-term prognosis for people with FEP. It has the potential to uncover a novel treatment that targets the neurobiological mechanisms of FEP and, if successful, will be a major advance for psychiatry. Trial registration Australian New Zealand Clinical Trials Registry, ID: ACTRN12618000413224. Registered on 21 March 2018.
Collapse
Affiliation(s)
- S M Cotton
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia. .,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia.
| | - M Berk
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia.,Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, School of Medicine, Geelong, VIC, Australia.,The Department of Psychiatry and the Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - A Watson
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - S Wood
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia.,School of Psychology, University of Birmingham, Edgbaston, UK
| | - K Allott
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - C F Bartholomeusz
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - C C Bortolasci
- Centre for Molecular and Medical Research, School of Medicine, Deakin University, Geelong, VIC, Australia
| | - K Walder
- Centre for Molecular and Medical Research, School of Medicine, Deakin University, Geelong, VIC, Australia
| | - B O'Donoghue
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - O M Dean
- Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, School of Medicine, Geelong, VIC, Australia.,The Department of Psychiatry and the Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - A Chanen
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - G P Amminger
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - P D McGorry
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - A Burnside
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - J Uren
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - A Ratheesh
- Orygen the National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, University of Melbourne, Locked Bag 10 (35 Poplar Road), Parkville, VIC, 3052, Australia.,Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia
| | - S Dodd
- Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University, School of Medicine, Geelong, VIC, Australia
| |
Collapse
|
45
|
Feldsine PT, Kerr DE, Leung SC, Lienau AH, Moser RF, Mui LA, Anderson G, Beasley M, Clements S, Dillon J, Dombroski P, Forgey R, Gartside S, Hernandez C, Hopkins S, Johnson K, Meier J, Nguyen T, Ortega R, Reynolds J, Smith J, Solis D, Summers C, Terry J, Tuncan E, Vrana D, Warren W, Wood S. Visual Immunoprecipitate Assay Eight Hour Method for Detection of Enterohemorrhagic Escherichia coli O157:H7 in Raw and Cooked Beef (Modification of AOAC Official Method 996.09): Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.5.1029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
AOAC Official Method 996.09, Visual Immunoprecipitate Assay (VIP®) for Escherichia coli O157:H7, was modified to incorporate a new enrichment protocol using BioControl EHEC8™ medium for testing raw and cooked beef. Foods were tested by VIP assay and the U.S. Department of Agriculture/Food Safety and Inspection Service (USDA/FSIS) enrichment procedure and the FDA Bacteriological Analytical Manual (BAM) isolation and confirmation techniques. A total of 15 collaborators participated. Raw and cooked ground beef were inoculated with E. coli O157:H7 at 2 different levels: a high level, where predominantly positive results were expect d, and a low level where fractional recovery was anticipated. Collaborators tested 396 test portions and controls by both methods, for a total of 792 test portions. Of the 396 paired test portions, 75 were positive and 230 were negative by both the VIP and culture methods. Eleven test portions were presumptively positive by VIP and could not be confirmed culturally; 32 were negative by VIP, but confirmed positive by culture; and 65 were negative by the culture method, but confirmed positive by the VIP method. There was no statistical difference between results obtained with the VIP for EHEC 8 h method and the culture method except for cooked beef, where the VIP had significantly higher recovery for one inoculation level.
Collapse
Affiliation(s)
| | - David E Kerr
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | | | - Andrew H Lienau
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | - Ruth F Moser
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | - Linda A Mui
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Feldsine PT, Kerr DE, Leung SC, Lienau AH, Miller SM, Mui LA, Anderson G, Beasley M, Dillon J, Dombroski P, Forgey R, Hernandez C, Hopkins S, Johnson K, Meier J, Nguyen T, Ortega R, Reynolds J, Smith J, Solis D, Summers C, Terry J, Tuncan E, Vrana D, Warren W, Wood S. Assurance® Enzyme Immunoassay Eight Hour Method for Detection of Enterohemorrhagic Escherichia coli O157:H7 in Raw and Cooked Beef (Modification of AOAC Official Method 996.10): Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.5.1037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
AOAC Official Method 996.10, Assurance® Enzyme Immunoassay (EIA) for Escherichia coli O157:H7 (EHEC), was modified to incorporate a new enrichment protocol using BioControl EHEC8™ medium for testing raw and cooked beef. Foods were tested by EIA and the U.S. Department of Agriculture/Food Safety and Inspection Service (USDA/FSIS) enrichment conditions and the FDA Bacteriological Analytical Manual (BAM) isolation and confirmation techniques. A total of 14 collaborators participated. Raw and cooked ground beef were inoculated with E. coli O157:H7 at 2 different levels: a high level where predominantly positive results were expected, and a low level where fractional recovery was anticipated. Collaborators tested 378 test portions and controls by both the 8 h EIA and the USDA/FSIS enrichment methods, for a total of 756 test portions. Of the 378 paired test portions, 75 were positive and 212 were negative by both methods. Thirteen test portions were presumptively positive by EIA and could not be confirmed culturally; 30 were negative by EIA, but confirmed positive by culture; and 65 were negative by the culture method, but confirmed positive by the EIA method. There was no statistical difference between results obtained with the Assurance EIA for EHEC 8 h method and the culture method for raw ground beef. The Assurance EIA had a significantly higher recovery for cooked beef.
Collapse
Affiliation(s)
| | - David E Kerr
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | | | - Andrew H Lienau
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | | | - Linda A Mui
- BioControl Systems, Inc., 12822 SE 32nd St, Bellevue, WA 98005
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Roberts H, Wood S, McNeil E, White R, Morgan S. Validation and implementation of a bespoke pan-cancer NGS panel for FFPE solid tumour analysis within an NHS setting. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Ramarao-Milne K, Patch AM, Nones K, Koufariotis R, Newell F, Addala V, Kondrashova O, Mukhopadhyay P, Kazakoff S, Lakis V, Holmes O, Leonard C, Wood S, Xu C, Pearson J, Hollway G, Waddell N. Detection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Mantri S, Wood S, Duda JE, Morley JF. Comparing self-reported and objective monitoring of physical activity in Parkinson disease. Parkinsonism Relat Disord 2019; 67:56-59. [DOI: 10.1016/j.parkreldis.2019.09.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 09/03/2019] [Accepted: 09/04/2019] [Indexed: 01/30/2023]
|
50
|
Siva S, Bressel M, Loi S, Sandhu S, Tran B, Mooi J, Lewin J, Azad A, Colyer D, Shaw M, Chander S, Cuff K, Wood S, Lawrentschuk N, Murphy D, Pryor D. MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.493] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|